https://trial.medpath.com/news/amgen-stock-slips-3-following-phase-3-data-for-rocatinlimab-uplizna-seeking-alpha 2024-09-25T01:47:06+00:00 weekly 0.7 https://trial.medpath.com/news/fda-cracks-down-on-counterfeit-ozempic-and-mounjaro-as-illegal-compounding-surges 2024-09-25T01:32:09+00:00 weekly 0.7 https://trial.medpath.com/news/epineuron-announces-health-canada-approval-of-the-peripulsetm-system-for-nerve-regeneration 2024-09-25T01:27:53+00:00 weekly 0.7 https://trial.medpath.com/news/enalare-receives-fda-clearance-to-initiate-the-first-phase-1-clinical-study-of-ena-001-to 2024-09-25T01:27:51+00:00 weekly 0.7 https://trial.medpath.com/news/ground-breaking-covid-19-antiviral-treatment-trial-opens-to-recruitment-nihr 2024-09-25T00:25:14+00:00 weekly 0.7 https://trial.medpath.com/news/piper-sandler-maintains-overweight-rating-on-acelyrin-shares 2024-09-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/caribou-biosciences-to-present-preclinical-data-on-cb-010-for-lupus-at-acr-convergence-2024 2024-09-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-helps-fredon-nj-man-find-leukemia-remission-hackensack-meridian-health 2024-09-24T23:55:04+00:00 weekly 0.7 https://trial.medpath.com/news/rheacell-announces-fda-approval-for-phase-3-study-in-refractory-non-curable-cvu-prleap 2024-09-24T23:07:14+00:00 weekly 0.7 https://trial.medpath.com/news/regulatory-approvals-and-governance-nihr 2024-09-24T22:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-pharma-secures-25m-loan-eyes-fda-drug-approval-investing-com 2024-09-24T21:24:39+00:00 weekly 0.7 https://trial.medpath.com/news/marstacimab-recommended-for-eu-approval-for-hemophilia-a-and-b 2024-09-24T21:07:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-gives-lupin-approval-for-bumetanide-injection-drug-store-news 2024-09-24T20:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/a-clinical-trial-has-halted-progression-of-merkel-cell-carcinoma-and-allowed-me-to-pursue 2024-09-24T20:34:41+00:00 weekly 0.7 https://trial.medpath.com/news/successful-clinical-trial-for-antibacterial-implants-by-aap-implantate-ag-webdisclosure 2024-09-24T20:23:53+00:00 weekly 0.7 https://trial.medpath.com/news/tepezza-r-teprotumumab-receives-approval-in-japan-for-the-treatment 2024-09-24T20:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/enfortumab-vedotin-combo-earns-japanese-approval-for-urothelial-carcinoma 2024-09-24T20:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/umass-chan-researchers-develop-dual-therapeutic-that-holds-promise-as-pancreatic-cancer 2024-09-24T19:59:21+00:00 weekly 0.7 https://trial.medpath.com/news/dod-awards-pitt-100m-for-trauma-trials-upmc 2024-09-24T19:32:55+00:00 weekly 0.7 https://trial.medpath.com/news/new-data-published-in-jaaos-demonstrates-breakthrough-therapy-zetafuse-yahoo-finance 2024-09-24T19:20:54+00:00 weekly 0.7 https://trial.medpath.com/news/eshoo-bill-to-improve-pediatric-drugs-passes-house-unanimously 2024-09-24T19:16:02+00:00 weekly 0.7 https://trial.medpath.com/news/nxera-pharma-receives-approval-of-quviviq-daridorexant-25-and-50-mg-in-japan-for-the 2024-09-24T19:13:11+00:00 weekly 0.7 https://trial.medpath.com/news/iomab-b-leads-to-more-durable-responses-vs-allohct-in-aml-treatment 2024-09-24T19:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/cutting-edge-multi-arm-octopus-trial-continues-to-progress-well-neurologylive 2024-09-24T19:09:02+00:00 weekly 0.7 https://trial.medpath.com/news/recon-japan-approves-lilly-s-alzheimer-s-drug-mhra-seeks-applicants-for-ai-airlock 2024-09-24T19:07:05+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-research-network-nihr 2024-09-24T18:55:01+00:00 weekly 0.7 https://trial.medpath.com/news/lipidor-ab-announces-first-patient-enrolled-in-phase-iii-study-of-akp02g2-for-topical 2024-09-24T18:49:14+00:00 weekly 0.7 https://trial.medpath.com/news/hesperos-provides-support-for-an-investigational-product-for-a-phase-ii-clinical-trial-with-its 2024-09-24T18:39:28+00:00 weekly 0.7 https://trial.medpath.com/news/the-odyssey-of-homer-comparative-effectiveness-research-on-medication-for-opioid-use 2024-09-24T18:30:56+00:00 weekly 0.7 https://trial.medpath.com/news/partiqol-trial-proton-therapy-vs-imrt-for-localized-prostate-cancer-jason-efstathiou 2024-09-24T18:14:23+00:00 weekly 0.7 https://trial.medpath.com/news/zkr-orthopedics-performs-first-u-s-patella-lift-procedure-initiating-fda-trial-biospace 2024-09-24T18:12:42+00:00 weekly 0.7 https://trial.medpath.com/news/b-braun-medical-receives-fda-clearance-for-introcan-safety-r-2-deep-access-iv-catheter 2024-09-24T18:12:10+00:00 weekly 0.7 https://trial.medpath.com/news/the-role-of-surgery-continues-to-evolve-in-seminoma-urology-times 2024-09-24T18:04:54+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-publish-critical-examination-of-new-brain-tumor-drug-medical-xpress 2024-09-24T17:54:06+00:00 weekly 0.7 https://trial.medpath.com/news/georgiamune-announces-first-participant-dosed-in-first-in-class-phase-1-healthy 2024-09-24T17:51:27+00:00 weekly 0.7 https://trial.medpath.com/news/aurinia-announces-japan-approval-of-lupkynis-r-voclosporin-to-treat-lupus-nephritis 2024-09-24T17:50:59+00:00 weekly 0.7 https://trial.medpath.com/news/senseonics-stock-down-despite-new-fda-approval-for-eversense-365-yahoo-finance 2024-09-24T17:47:35+00:00 weekly 0.7 https://trial.medpath.com/news/transgene-to-report-major-clinical-data-before-the-end-of-2024-confirmed-financial 2024-09-24T17:38:02+00:00 weekly 0.7 https://trial.medpath.com/news/inexpensive-drug-can-prevent-cerebral-palsy-in-premature-babies-cochrane 2024-09-24T17:26:16+00:00 weekly 0.7 https://trial.medpath.com/news/renal-cancer-clinical-trial-pipeline-appears-robust-with-75-key-pharma-companies 2024-09-24T17:17:35+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-roflumilast-s-snda-to-treat-scalp-and-body-psoriasis-in-adolescents-adults 2024-09-24T17:07:58+00:00 weekly 0.7 https://trial.medpath.com/news/cerapedics-i-factor-p-15-peptide-enhanced-bone-graft-a-trusted-choice-ortho-spine-news 2024-09-24T16:50:06+00:00 weekly 0.7 https://trial.medpath.com/news/clene-granted-in-person-fda-meeting-on-cnm-au8-for-als-als-news-today 2024-09-24T16:17:55+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-s-kisunlatm-donanemab-azbt-approved-in-japan-for-the-treatment-of-early-pr-newswire 2024-09-24T16:00:54+00:00 weekly 0.7 https://trial.medpath.com/news/re-cognition-health-usa-achieves-gcsa-clinical-trial-site-certification-contract-pharma 2024-09-24T15:45:43+00:00 weekly 0.7 https://trial.medpath.com/news/enrollment-complete-of-phase-2b-of-siglec-study-to-assess-safety-and-efficacy-of-avd-104 2024-09-24T15:14:04+00:00 weekly 0.7 https://trial.medpath.com/news/new-weight-loss-biotech-metsera-stuns-with-7-5-weight-loss-few-side-effects 2024-09-24T15:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/nevro-wins-fda-nod-for-ai-driven-spinal-cord-stimulation-tech-massdevice 2024-09-24T15:04:46+00:00 weekly 0.7 https://trial.medpath.com/news/ainos-spotlighted-in-water-tower-research-report-on-veldona-clinical-study-for-stock-titan 2024-09-24T15:03:42+00:00 weekly 0.7 https://trial.medpath.com/news/neurosense-therapeutics-granted-key-u-s-patent-for-novel-primec-formulation-its-lead 2024-09-24T14:46:58+00:00 weekly 0.7 https://trial.medpath.com/news/alxn2220-for-attr-amyloidosis-with-cardiomyopathy-granted-fast-track-designation 2024-09-24T14:46:50+00:00 weekly 0.7 https://trial.medpath.com/news/combination-targeted-therapy-produces-durable-remissions-in-some-patients-the-asco-post 2024-09-24T14:30:19+00:00 weekly 0.7 https://trial.medpath.com/news/nomic-r-and-parker-institute-for-cancer-immunotherapy-pici-launch-large-scale-protein 2024-09-24T13:45:19+00:00 weekly 0.7 https://trial.medpath.com/news/china-medical-system-new-drug-application-for-vitiligo-indication-of-ruxolitinib-phosphate 2024-09-24T13:39:28+00:00 weekly 0.7 https://trial.medpath.com/news/cardiol-therapeutics-reaches-target-enrollment-for-phase-ii-acute-myocarditis-trial 2024-09-24T13:13:16+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-immunotherapy-for-dmmr-and-pmmr-colorectal-cancers-nature 2024-09-24T13:12:25+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-results-show-low-intensity-therapy-can-achieve-positive-outcomes-for-certain 2024-09-24T13:01:12+00:00 weekly 0.7 https://trial.medpath.com/news/synergia-implants-first-patients-with-neurostimulator-for-epilepsy-treatment 2024-09-24T12:53:46+00:00 weekly 0.7 https://trial.medpath.com/news/low-intensity-repetitive-transcranial-magnetic-stimulation-enhances-myelin-repair-in-pre 2024-09-24T12:50:50+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-sciences-announces-completion-of-an-interim-safety-review-of-oral-simufilam-on 2024-09-24T12:41:41+00:00 weekly 0.7 https://trial.medpath.com/news/psychedelic-therapies-are-coming-to-europe-but-face-barriers-before-reaching-patients 2024-09-24T12:39:02+00:00 weekly 0.7 https://trial.medpath.com/news/enlivex-announces-positive-dsmb-recommendation-to-initiate-globenewswire 2024-09-24T12:36:23+00:00 weekly 0.7 https://trial.medpath.com/news/cytodyn-announces-preliminary-findings-in-study-with-smc-laboratories 2024-09-24T12:30:46+00:00 weekly 0.7 https://trial.medpath.com/news/aurion-biotech-launches-vyznova-r-neltependocel-in-japan-for-the-treatment-of-bullous 2024-09-24T12:28:06+00:00 weekly 0.7 https://trial.medpath.com/news/ksq-therapeutics-announces-fda-clearance-of-ind-application-for-ksq-004ex-a-crispr 2024-09-24T12:23:20+00:00 weekly 0.7 https://trial.medpath.com/news/cpec-phase-ii-is-going-to-start-finance-minister-aaj-news 2024-09-24T12:17:03+00:00 weekly 0.7 https://trial.medpath.com/news/unity-biotechnology-to-host-in-person-ophthalmology-day-in-new-york-on-tuesday 2024-09-24T12:12:27+00:00 weekly 0.7 https://trial.medpath.com/news/univo-irb-launches-canadian-research-ethics-board-review-services-for-clinical-trials-in 2024-09-24T12:11:54+00:00 weekly 0.7 https://trial.medpath.com/news/silexion-therapeutics-announces-significant-new-data-from-phase-2-trial-of-lodertm-in 2024-09-24T11:48:30+00:00 weekly 0.7 https://trial.medpath.com/news/zevra-therapeutics-to-present-top-line-data-from-the-phase-2-clinical-trial-of-kp1077-for 2024-09-24T11:48:24+00:00 weekly 0.7 https://trial.medpath.com/news/wave-life-sciences-announces-positive-interim-data-from-forward-53-clinical-trial 2024-09-24T11:33:10+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-ucb-get-the-lupus-data-they-ve-waited-two-decades-for-biopharma-dive 2024-09-24T11:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/united-therapeutics-to-feature-clinical-data-across-its-commercial-and-development 2024-09-24T11:04:16+00:00 weekly 0.7 https://trial.medpath.com/news/mre-and-te-show-limited-accuracy-in-detecting-advanced-liver-fibrosis-in-pediatric-masld-patients 2024-09-24T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-funding-to-better-understand-causes-of-rare-cancers-and-their-responses-to-targeted-therapy 2024-09-24T10:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-cluster-randomized-study-of-technology-assisted-health-coaching-for-weight 2024-09-24T10:12:07+00:00 weekly 0.7 https://trial.medpath.com/news/lsu-lcmc-health-cancer-center-experts-discuss-advances-in-research-and-goals-for-a 2024-09-24T10:02:24+00:00 weekly 0.7 https://trial.medpath.com/news/senate-confronts-novo-nordisk-over-semaglutide-pricing-demands-u-s-price-parity-with-europe 2024-09-24T09:46:54+00:00 weekly 0.7 https://trial.medpath.com/news/popular-diabetes-drug-metformin-may-slow-aging-study-finds-cbs-news 2024-09-24T09:38:36+00:00 weekly 0.7 https://trial.medpath.com/news/psilocybin-may-curb-mental-illness-that-leads-to-eating-disorders 2024-09-24T09:09:27+00:00 weekly 0.7 https://trial.medpath.com/news/algotx-announces-last-patient-last-visit-in-international-phase-ii-trial-of-atx01-in-morningstar 2024-09-24T07:53:57+00:00 weekly 0.7 https://trial.medpath.com/news/experts-discuss-treatment-strategies-and-challenges-in-managing-chronic-gvhd-after-stem-cell-transplantation 2024-09-24T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/chugai-receives-approvals-for-additional-indication-of-evrysdi-in-pre-symptomatic-spinal 2024-09-24T06:38:34+00:00 weekly 0.7 https://trial.medpath.com/news/medicare-drug-price-negotiations-pose-complex-challenges-for-community-oncology-practices 2024-09-24T06:26:29+00:00 weekly 0.7 https://trial.medpath.com/news/why-industry-must-design-alzheimer-s-trials-to-include-people-with-down-syndrome 2024-09-24T06:14:40+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-s-menveo-meningococcal-vaccine-in-new-single-vial-fully-liquid-presentation-receives 2024-09-24T06:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/nfl-legend-brett-favre-reveals-parkinson-s-disease-diagnosis-amid-congressional-testimony 2024-09-24T05:22:45+00:00 weekly 0.7 https://trial.medpath.com/news/basilea-initiates-clinical-phase-3-study-with-antifungal-globenewswire 2024-09-24T05:21:19+00:00 weekly 0.7 https://trial.medpath.com/news/santhera-announces-acceptance-by-swissmedic-of-marketing-authorization-application-for 2024-09-24T05:10:16+00:00 weekly 0.7 https://trial.medpath.com/news/opensafely-platform-revolutionizes-big-data-medical-research-with-enhanced-privacy-protection 2024-09-24T05:01:50+00:00 weekly 0.7 https://trial.medpath.com/news/amr-accelerator-urges-long-term-funding-european-biotechnology-magazine 2024-09-24T04:11:22+00:00 weekly 0.7 https://trial.medpath.com/news/lighting-the-way-to-pain-relief-drug-discovery-news 2024-09-24T04:03:47+00:00 weekly 0.7 https://trial.medpath.com/news/leading-neuro-oncologist-emphasizes-importance-of-proactive-mentorship-in-brain-cancer-research 2024-09-24T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-announces-data-presentations-on-tnx-102-sl-for-fibromyalgia-at 2024-09-24T03:56:28+00:00 weekly 0.7 https://trial.medpath.com/news/new-model-identifies-cancer-patients-at-high-risk-for-er-visits-during-clinical-trials 2024-09-24T02:51:43+00:00 weekly 0.7 https://trial.medpath.com/news/reconsidering-rems-mandate-may-improve-car-t-cell-therapy-accessibility 2024-09-24T02:04:14+00:00 weekly 0.7 https://trial.medpath.com/news/detecting-clear-cell-renal-cell-carcinoma-use-of-zr-89-girentuximab-pet-ct-imaging 2024-09-24T01:56:15+00:00 weekly 0.7 https://trial.medpath.com/news/south-korean-study-finds-fecal-microbiota-transplants-may-help-patients-with-dark-daily 2024-09-24T01:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/neurosense-regains-compliance-with-nasdaq-minimum-bid-price-rule 2024-09-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-unveils-tags-technology-revolutionary-multi-pathogen-detection-system-for-infectious-diseases 2024-09-23T23:17:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-leo-pharmas-filing-of-delgocitinib-cream-new-drug-application-for-the-treatment-of-chronic-hand-eczema 2024-09-23T23:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/cenna-biosciences-receives-nih-nia-phase-ii-sbir-award-for-the-early-clinical-yahoo-finance 2024-09-23T22:53:14+00:00 weekly 0.7 https://trial.medpath.com/news/effectiveness-of-rimegepant-further-displayed-in-pooled-phase-3-analysis-neurologylive 2024-09-23T22:08:36+00:00 weekly 0.7 https://trial.medpath.com/news/former-orphazyme-drug-arimoclomol-approved-by-fda-medwatch 2024-09-23T21:58:28+00:00 weekly 0.7 https://trial.medpath.com/news/vicebio-secures-100m-to-advance-rsv-and-hmpv-vaccine-combo-to-phase-i 2024-09-23T21:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/aptar-s-n-sorb-nitrosamine-mitigation-solution-accepted-to-us-fda-s-emerging-technology-program 2024-09-23T21:11:53+00:00 weekly 0.7 https://trial.medpath.com/news/dbv-technologies-completes-screening-for-the-vitesse-phase-3-clinical-trial 2024-09-23T21:04:11+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-supports-adding-ruxolitinib-to-tyrosine-kinase-inhibitors-for-chronic-myeloid-leukemia 2024-09-23T21:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/frontiers-effects-of-active-breaks-on-educational-achievement-in-children-with-and-without-adhd 2024-09-23T20:59:40+00:00 weekly 0.7 https://trial.medpath.com/news/orthopaedic-surgery-supports-pediatric-patients-through-cancer-diagnosis-treatment 2024-09-23T20:56:46+00:00 weekly 0.7 https://trial.medpath.com/news/aavantgarde-bio-doses-first-patient-in-trial-for-usher-syndrome-gene-therapy-aavb-081 2024-09-23T20:30:21+00:00 weekly 0.7 https://trial.medpath.com/news/watchful-waiting-noninferior-to-bcg-for-resected-high-grade-pt1-bladder-cancer 2024-09-23T20:14:37+00:00 weekly 0.7 https://trial.medpath.com/news/transdermal-estradiol-may-offer-another-option-for-high-risk-prostate-cancer 2024-09-23T20:14:36+00:00 weekly 0.7 https://trial.medpath.com/news/mercy-now-offering-proton-beam-clinical-trials-spectrum-news 2024-09-23T18:03:03+00:00 weekly 0.7 https://trial.medpath.com/news/biohaven-achieves-positive-topline-results-in-pivotal-study-of-troriluzole-in-pr-newswire 2024-09-23T18:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/wicker-celebrates-new-innovation-hub-tackling-rare-diseases-u-s-senator-roger 2024-09-23T17:27:25+00:00 weekly 0.7 https://trial.medpath.com/news/apellis-stock-down-as-eye-drug-faces-third-chmp-rejection-in-the-eu-yahoo-finance 2024-09-23T17:25:36+00:00 weekly 0.7 https://trial.medpath.com/news/pancreatic-cancer-the-clinical-trial-landscape-and-progress-for-2024 2024-09-23T17:15:35+00:00 weekly 0.7 https://trial.medpath.com/news/short-course-of-treatment-with-rns60-extends-survival-in-als-als-news-today 2024-09-23T16:50:04+00:00 weekly 0.7 https://trial.medpath.com/news/dundee-research-reveals-breakthrough-for-tough-cancers-mirage-news 2024-09-23T16:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/patient-directed-education-to-promote-deprescribing-a-nonrandomized-clinical-trial 2024-09-23T16:14:33+00:00 weekly 0.7 https://trial.medpath.com/news/us-whooping-cough-cases-rising-especially-in-teens-cdc-says-empr-com 2024-09-23T16:03:58+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-announces-positive-interim-phase-2-data-for-darovasertib-pr-newswire 2024-09-23T16:02:12+00:00 weekly 0.7 https://trial.medpath.com/news/novel-approach-to-evaluate-the-role-of-selexipag-in-pulmonary-arterial-hypertension 2024-09-23T15:27:59+00:00 weekly 0.7 https://trial.medpath.com/news/first-line-serplulimab-receives-positive-chmp-opinion-for-es-sclc-onclive 2024-09-23T15:23:51+00:00 weekly 0.7 https://trial.medpath.com/news/cidara-therapeutics-announces-first-subjects-dosed-in-phase-2b-navigate-trial 2024-09-23T15:09:20+00:00 weekly 0.7 https://trial.medpath.com/news/black-diamond-therapeutics-announces-initial-phase-2-data-demonstrating-robust-biospace 2024-09-23T15:09:20+00:00 weekly 0.7 https://trial.medpath.com/news/ca-pharma-co-reports-positive-phase-3-data-for-schizophrenia-treatment 2024-09-23T14:58:55+00:00 weekly 0.7 https://trial.medpath.com/news/cu-cancer-center-research-tests-two-drug-treatment-for-progressive-thyroid-cancer 2024-09-23T14:56:23+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-pharma-gets-nod-to-launch-cancer-drug-durvalumab-in-india-cnbc-tv18 2024-09-23T14:52:48+00:00 weekly 0.7 https://trial.medpath.com/news/fragile-x-held-him-back-an-experimental-drug-is-helping-him-break-free-npr 2024-09-23T14:26:52+00:00 weekly 0.7 https://trial.medpath.com/news/charlotte-dna-repair-research-may-influence-cancer-clinical-trials 2024-09-23T14:26:50+00:00 weekly 0.7 https://trial.medpath.com/news/apps-offer-a-unique-lens-to-myeloma-care-oncology-nursing-news 2024-09-23T14:09:35+00:00 weekly 0.7 https://trial.medpath.com/news/university-of-cincinnati-cancer-center-hosts-phase-3-prostate-cancer-trial 2024-09-23T13:52:07+00:00 weekly 0.7 https://trial.medpath.com/news/new-ai-model-enhances-clinical-trial-approval-predictions-by-quantifying-uncertainty 2024-09-23T13:51:41+00:00 weekly 0.7 https://trial.medpath.com/news/us-filing-accepted-for-new-growth-hope-for-leo-pharma-medwatch 2024-09-23T13:48:48+00:00 weekly 0.7 https://trial.medpath.com/news/sylvester-researchers-expand-ovarian-cancer-study-to-africa 2024-09-23T13:45:30+00:00 weekly 0.7 https://trial.medpath.com/news/lantern-pharma-announces-three-u-s-fda-rare-pediatric-disease-designations-granted 2024-09-23T13:20:37+00:00 weekly 0.7 https://trial.medpath.com/news/realta-life-sciences-announces-first-patient-dosed-in-phase-2-study-evaluating-rls-0071 2024-09-23T13:20:37+00:00 weekly 0.7 https://trial.medpath.com/news/readout-newsletter-biohaven-daiichi-sankyo-astrazeneca-news-stat-news 2024-09-23T13:17:16+00:00 weekly 0.7 https://trial.medpath.com/news/bonafide-r-health-launches-thermellatm-the-first-and-only-hormone-free-prescription 2024-09-23T13:06:58+00:00 weekly 0.7 https://trial.medpath.com/news/kazia-therapeutics-announces-presentation-of-evt801-clinical-data-at-15th-biennial-stock-titan 2024-09-23T13:00:12+00:00 weekly 0.7 https://trial.medpath.com/news/vistagen-initiates-palisade-4-phase-3-study-of-fasedienol-for-the-acute-treatment-stock-titan 2024-09-23T12:50:41+00:00 weekly 0.7 https://trial.medpath.com/news/immusoft-to-announce-positive-phase-1-data-for-first-engineered-b-cell-therapy-in-a-clinical-trial 2024-09-23T12:30:49+00:00 weekly 0.7 https://trial.medpath.com/news/rivus-pharmaceuticals-to-present-new-data-from-phase-2a-humain-trial-of-hu6-pr-newswire 2024-09-23T12:23:39+00:00 weekly 0.7 https://trial.medpath.com/news/therivatm-biologics-achieves-target-patient-enrollment-in-the-virage-phase-2b-trial-of 2024-09-23T12:17:24+00:00 weekly 0.7 https://trial.medpath.com/news/oryzon-presents-the-final-data-from-portico-a-global-phase-iib-vafidemstat-trial-in 2024-09-23T12:14:43+00:00 weekly 0.7 https://trial.medpath.com/news/assembly-biosciences-reports-positive-interim-phase-1a-results-from-clinical-trial 2024-09-23T12:14:43+00:00 weekly 0.7 https://trial.medpath.com/news/carrick-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-ct7439 2024-09-23T12:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/ipsen-s-kayfanda-r-odevixibat-approved-in-european-union-for-cholestatic-pruritus-in 2024-09-23T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/elevation-oncology-receives-fast-track-designation-from-the-fda-for-eo-3021-for-pr-newswire 2024-09-23T11:33:06+00:00 weekly 0.7 https://trial.medpath.com/news/priovant-therapeutics-announces-receipt-of-fast-track-designation-from-fda-for-pr-newswire 2024-09-23T11:33:06+00:00 weekly 0.7 https://trial.medpath.com/news/uniqure-announces-orphan-drug-designation-granted-globenewswire 2024-09-23T11:20:14+00:00 weekly 0.7 https://trial.medpath.com/news/heidelberg-pharma-announces-new-clinical-data-on-lead-atac-candidate-hdp-101-to-be 2024-09-23T11:08:07+00:00 weekly 0.7 https://trial.medpath.com/news/prestige-biopharma-secures-ec-approval-for-herceptin-biosimilar-tuznue-kbr 2024-09-23T11:04:45+00:00 weekly 0.7 https://trial.medpath.com/news/takeda-s-fruquintinib-gains-mhra-approval-for-colorectal-cancer 2024-09-23T11:02:29+00:00 weekly 0.7 https://trial.medpath.com/news/alkermes-to-present-positive-clinical-data-from-phase-1b-study-of-alks-2680-in-patients 2024-09-23T11:02:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-sirb-mandate-a-chance-to-reassess-site-performance-contract-pharma 2024-09-23T11:01:14+00:00 weekly 0.7 https://trial.medpath.com/news/effects-of-medicaid-coverage-on-cardiovascular-health-outcomes-the-bmj 2024-09-23T10:25:16+00:00 weekly 0.7 https://trial.medpath.com/news/therma-bright-investment-portfolio-company-instatin-secures-mountain-west-research 2024-09-23T10:14:18+00:00 weekly 0.7 https://trial.medpath.com/news/pdcs-vs-adcs-a-new-frontier-in-targeted-cancer-therapies-and-the-potential-for 2024-09-23T10:12:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-leo-pharma-s-filing-of-delgocitinib-cream-new-drug-application-for-the 2024-09-23T10:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/could-antidepressants-give-memory-a-boost 2024-09-23T09:09:29+00:00 weekly 0.7 https://trial.medpath.com/news/diabetes-treatment-might-ease-gum-disease-too 2024-09-23T09:09:09+00:00 weekly 0.7 https://trial.medpath.com/news/antengene-announces-xpovio-r-selinexor-approved-for-commercialization-in-thailand 2024-09-23T09:02:10+00:00 weekly 0.7 https://trial.medpath.com/news/largest-collection-of-sarcoma-patient-derived-organoids-pave-the-way-for-personalized 2024-09-23T08:57:23+00:00 weekly 0.7 https://trial.medpath.com/news/new-biological-findings-open-the-door-to-improved-outcomes-for-young-adults-with-sarcoma 2024-09-23T08:14:03+00:00 weekly 0.7 https://trial.medpath.com/news/bajaj-healthcare-soars-7-after-pact-with-european-firm-for-new-api-business-standard 2024-09-23T07:30:39+00:00 weekly 0.7 https://trial.medpath.com/news/medicare-s-2-drug-list-model-could-benefit-38-of-beneficiaries-with-modest-cost-savings 2024-09-23T07:02:27+00:00 weekly 0.7 https://trial.medpath.com/news/ai-shows-promise-and-limitations-across-multiple-cancer-care-applications 2024-09-23T06:00:10+00:00 weekly 0.7 https://trial.medpath.com/news/relief-therapeutics-announces-2-million-milestone-under-royalty-sales-agreement 2024-09-23T05:07:46+00:00 weekly 0.7 https://trial.medpath.com/news/innate-pharma-announces-fda-clearance-of-the-ind-for-iph4502-a-nectin-4-adc-to-be 2024-09-23T05:07:18+00:00 weekly 0.7 https://trial.medpath.com/news/ucb-announces-u-s-fda-approvals-for-bimzelx-r-bimekizumab-bkzx-for-the-treatment 2024-09-23T05:01:37+00:00 weekly 0.7 https://trial.medpath.com/news/in-trials-a-powerful-magnet-for-zapping-alzheimer-s-away-being-patient 2024-09-23T04:41:25+00:00 weekly 0.7 https://trial.medpath.com/news/pepgen-to-release-duchenne-muscular-dystrophy-drug-trial-results-in-mid-2024 2024-09-23T03:15:39+00:00 weekly 0.7 https://trial.medpath.com/news/hlb-reapply-for-liver-cancer-drug-approval-from-fda-businesskorea 2024-09-23T02:12:42+00:00 weekly 0.7 https://trial.medpath.com/news/tumour-response-in-sixth-patient-triggers-additional-recruitment-in-pancreatic-cancer-trial 2024-09-23T00:27:08+00:00 weekly 0.7 https://trial.medpath.com/news/msd-receives-singapore-health-sciences-authority-hsa-approval-for 2024-09-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aerify-1-2-trials-evaluating-itepekimab-for-moderate-to-severe-copd-in-former-smokers 2024-09-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/synergia-medical-successfully-implants-first-patients-with-nao-vns-system 2024-09-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cost-utility-and-budget-impact-analysis-of-adding-sglt-2-inhibitors-to-standard-treatment 2024-09-22T23:03:09+00:00 weekly 0.7 https://trial.medpath.com/news/proteomics-international-laboratories-ltd-asx-piq-esophageal-cancer-diagnostic 2024-09-22T23:01:20+00:00 weekly 0.7 https://trial.medpath.com/news/registration-of-cytostatic-effects-on-cultured-cells-in-vitro-and-their-current-significance-pubmed 2024-09-22T22:39:45+00:00 weekly 0.7 https://trial.medpath.com/news/this-immigrant-just-became-a-biotech-billionaire-forbes-australia 2024-09-22T22:07:21+00:00 weekly 0.7 https://trial.medpath.com/news/this-stock-is-crushing-nvidia-s-performance-this-year-is-it-too-late-to-buy 2024-09-22T20:28:40+00:00 weekly 0.7 https://trial.medpath.com/news/canaritech-announces-the-launch-of-operations-offering-comprehensive-clinical-trial 2024-09-22T20:09:15+00:00 weekly 0.7 https://trial.medpath.com/news/ovarian-function-suppression-may-benefit-select-breast-cancer-populations 2024-09-22T19:57:13+00:00 weekly 0.7 https://trial.medpath.com/news/buy-rating-reaffirmed-for-apellis-pharmaceuticals-amid-market-overreaction-and-promising 2024-09-22T17:33:45+00:00 weekly 0.7 https://trial.medpath.com/news/black-diamond-therapeutics-to-host-webcast-presentation-of-initial-phase-2-bdtx-1535 2024-09-22T16:33:36+00:00 weekly 0.7 https://trial.medpath.com/news/most-cancer-drugs-must-now-be-tested-in-paediatric-cancers-unique-pdx-models-can-help-nature 2024-09-22T16:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/tapotoclax-demonstrates-safety-yields-anti-leukemic-effects-but-no-responses-in-mds 2024-09-22T16:08:40+00:00 weekly 0.7 https://trial.medpath.com/news/epstein-barr-virus-immune-response-specific-to-multiple-sclerosis-relative-to-other 2024-09-22T16:06:42+00:00 weekly 0.7 https://trial.medpath.com/news/lunning-evaluates-car-t-cell-therapy-for-asct-eligible-and-ineligible-dlbcl 2024-09-22T15:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/faster-identification-of-infants-at-high-risk-of-rop-by-evaluating-the-effects-of-maternal-and 2024-09-22T15:05:07+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-data-affirm-enduring-responses-with-teclistamab-in-r-r-multiple-myeloma 2024-09-22T14:10:42+00:00 weekly 0.7 https://trial.medpath.com/news/pfspz-vaccine-shows-efficacy-against-p-falciparum-and-malaria-in-women-who-become-pregnant 2024-09-22T13:44:14+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-announces-webcast-to-report-interim-phase-2-data-for-darovasertib-and 2024-09-22T13:02:11+00:00 weekly 0.7 https://trial.medpath.com/news/bwc0977-a-new-approach-to-antimicrobial-resistance-contagion-live 2024-09-22T11:29:14+00:00 weekly 0.7 https://trial.medpath.com/news/hong-kong-team-to-enrol-3000-patients-to-improve-ai-tool-targeting-cardiovascular-disease 2024-09-22T11:23:41+00:00 weekly 0.7 https://trial.medpath.com/news/imaging-study-offers-insights-on-mechanism-behind-bcg-resistance-in-nmibc 2024-09-22T10:17:14+00:00 weekly 0.7 https://trial.medpath.com/news/screening-for-colon-cancer-could-expand-with-a-convenient-alternative-if-fda-approves-new 2024-09-22T10:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/whooping-cough-cases-are-soaring-can-infecting-people-help-test-a-better-vaccine 2024-09-22T08:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/this-week-s-awesome-tech-stories-from-around-the-web-through-september-21 2024-09-22T07:54:57+00:00 weekly 0.7 https://trial.medpath.com/news/men-get-breast-cancer-too-but-they-can-t-always-access-new-drugs-cbc-news 2024-09-22T07:04:19+00:00 weekly 0.7 https://trial.medpath.com/news/ibcn-2024-molecular-subtypes-and-outcomes-in-the-vesper-trial-urotoday 2024-09-22T07:01:57+00:00 weekly 0.7 https://trial.medpath.com/news/who-evaluates-india-s-top-drug-regulator-vaccine-manufacturing-practices 2024-09-22T07:00:06+00:00 weekly 0.7 https://trial.medpath.com/news/oncology-leaders-emphasize-cautious-ai-implementation-to-maintain-physician-trust 2024-09-22T05:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/expert-reaction-to-6-month-follow-up-of-phase-2-trial-of-psilocybin-versus-escitalopram-for-depression 2024-09-22T05:43:13+00:00 weekly 0.7 https://trial.medpath.com/news/relacorilant-or-surgery-improved-hemostatic-markers-in-cushing-syndrome 2024-09-22T05:08:51+00:00 weekly 0.7 https://trial.medpath.com/news/comparative-cost-effectiveness-of-atezolizumab-versus-durvalumab-as-first-line 2024-09-22T05:07:17+00:00 weekly 0.7 https://trial.medpath.com/news/end-of-dose-phenomena-observed-with-multiple-sclerosis-medication-ofatumumab 2024-09-22T04:50:53+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-psychedelic-drug-psilocybin-gives-eurekalert 2024-09-22T02:11:13+00:00 weekly 0.7 https://trial.medpath.com/news/sustained-reductions-of-brain-atrophy-observed-with-s1p-modulator-ozanimod 2024-09-22T01:05:54+00:00 weekly 0.7 https://trial.medpath.com/news/stealth-biotherapeutics-presents-preclinical-data-on-bevemipretide-s-retinal-delivery-in-amd-models 2024-09-21T22:18:23+00:00 weekly 0.7 https://trial.medpath.com/news/benefit-of-whole-pelvis-radiation-for-patients-with-muscle-invasive-bladder-cancer 2024-09-21T21:37:11+00:00 weekly 0.7 https://trial.medpath.com/news/expediting-clinical-trial-processes-to-advance-brain-cancer-research 2024-09-21T20:50:26+00:00 weekly 0.7 https://trial.medpath.com/news/exploring-gprc5d-as-an-important-target-for-multiple-myeloma-cancer-network 2024-09-21T20:50:25+00:00 weekly 0.7 https://trial.medpath.com/news/bladder-cancer-breakthroughs-in-sunrise-1-ambassador-and-volga-trials-maria-de-santis 2024-09-21T20:43:53+00:00 weekly 0.7 https://trial.medpath.com/news/tiziana-life-sciences-announces-4-million-grant-awarded-by-nih-to-study-anti-cd3-in 2024-09-21T20:28:50+00:00 weekly 0.7 https://trial.medpath.com/news/vietnam-launches-vaccination-against-dengue-fever-nationwide-for-first-time-tuoi-tre-news 2024-09-21T19:25:55+00:00 weekly 0.7 https://trial.medpath.com/news/ibcn-2024-using-urinary-genomic-disease-burden-to-assess-cretostimogene-grenadenorepvec 2024-09-21T18:48:11+00:00 weekly 0.7 https://trial.medpath.com/news/teva-presents-new-phase-3-efficacy-safety-and-tolerability-data-from-solaris-trial-stock-titan 2024-09-21T18:26:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-isatuximab-plus-vrd-for-newly-diagnosed-transplant-ineligible-multiple-myeloma 2024-09-21T16:53:44+00:00 weekly 0.7 https://trial.medpath.com/news/a-randomized-multicenter-phase-3-clinical-trial-evaluating-intracanal-opth 2024-09-21T16:17:42+00:00 weekly 0.7 https://trial.medpath.com/news/disparities-in-time-to-oral-antimyeloma-treatment-shown-in-new-study 2024-09-21T15:58:08+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-of-cilta-cel-is-maintained-in-early-relapsed-multiple-myeloma-targeted-oncology 2024-09-21T15:58:07+00:00 weekly 0.7 https://trial.medpath.com/news/btk-inhibitor-therapy-can-be-stopped-in-cll-targeted-oncology 2024-09-21T15:58:07+00:00 weekly 0.7 https://trial.medpath.com/news/ectrims-2024-high-dose-vitamin-d-can-help-delay-progression-to-ms 2024-09-21T15:47:20+00:00 weekly 0.7 https://trial.medpath.com/news/niger-latest-african-country-to-launch-malaria-vaccine-medical-xpress 2024-09-21T15:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/lenalidomide-obinutuzumab-combo-yields-promising-results-in-relapsed-nhl 2024-09-21T14:26:19+00:00 weekly 0.7 https://trial.medpath.com/news/fight-retinal-blindness-spain-report-3-clinical-outcomes-of-vascular-endothelial-growth 2024-09-21T14:08:21+00:00 weekly 0.7 https://trial.medpath.com/news/armour-s-mononine-monoclonal-factor-ix-approved-by-fda-pink-sheet 2024-09-21T14:05:33+00:00 weekly 0.7 https://trial.medpath.com/news/ibcn-2024-eg-70-detalimogene-voraplasmid-a-novel-non-viral-intravesical-gene 2024-09-21T14:02:58+00:00 weekly 0.7 https://trial.medpath.com/news/new-clinical-trial-in-kenya-could-move-needle-in-cancer-treatment-the-standard-health 2024-09-21T13:48:09+00:00 weekly 0.7 https://trial.medpath.com/news/gene-and-cell-therapy-approaches-hold-promise-for-usher-syndrome-cgtlive-r 2024-09-21T13:13:28+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-glp-1-drugs-may-prevent-3400-heart-attacks-strokes-a-year-healthline 2024-09-21T12:23:19+00:00 weekly 0.7 https://trial.medpath.com/news/expert-dermatologist-outlines-key-diagnostic-criteria-for-urticaria-at-maui-derm-conference 2024-09-21T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-highlights-variable-efficacy-of-aspirin-dosing-during-pregnancy 2024-09-21T11:35:23+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-stock-roundup-fda-approvals-for-lly-mrk-azn-jnj-drugs-yahoo-finance 2024-09-21T11:12:45+00:00 weekly 0.7 https://trial.medpath.com/news/president-and-ceo-harris-todd-sold-394441-worth-of-shares-16307-units-at-24-19 2024-09-21T10:44:46+00:00 weekly 0.7 https://trial.medpath.com/news/high-throughput-identification-of-repurposable-neuroactive-drugs-with-potent-anti-nature 2024-09-21T10:19:08+00:00 weekly 0.7 https://trial.medpath.com/news/first-line-combo-yields-strong-results-in-advanced-sarcoma 2024-09-21T10:11:02+00:00 weekly 0.7 https://trial.medpath.com/news/chief-medical-officer-conner-edward-r-exercised-4790-shares-at-a-strike-of-4-20-and-sold 2024-09-21T09:51:57+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-propels-zvra-to-52-week-high-adma-cprx-tvtx-also-reach-new-peaks 2024-09-21T08:27:23+00:00 weekly 0.7 https://trial.medpath.com/news/ncpa-intensifies-campaign-for-pbm-reform-as-congressional-deadline-looms 2024-09-21T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-shingles-reactivation-could-occur-in-rare-cases-following-rzv-pharmacy-times 2024-09-21T07:26:01+00:00 weekly 0.7 https://trial.medpath.com/news/capivasertib-shows-promise-in-er-her2-metastatic-breast-cancer-with-pik3ca-mutations 2024-09-21T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-metabolic-disruption-discovered-in-sma-patients-n-acetylneuraminic-acid-shows-treatment-potential 2024-09-21T06:28:00+00:00 weekly 0.7 https://trial.medpath.com/news/apellis-shares-dip-as-mizuho-cuts-price-target-keeps-neutral-rating-investing-com-canada 2024-09-21T05:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/biohaven-announces-conference-call-to-discuss-topline-pivotal-study-results-in-pr-newswire 2024-09-21T05:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/novel-pan-immune-inflammation-nomogram-shows-promise-in-predicting-epithelial-ovarian-cancer-outcomes 2024-09-21T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rachna-shroff-on-advanced-hepatocellular-carcinoma-anlotinib-plus-penpulimab-vs-sorafenib 2024-09-21T04:54:50+00:00 weekly 0.7 https://trial.medpath.com/news/simvastatin-fails-to-reduce-disease-progression-in-phase-3-ms-stat2-trial-of-secondary 2024-09-21T04:41:10+00:00 weekly 0.7 https://trial.medpath.com/news/university-of-arkansas-for-medical-sciences-receives-2-2-million-grant-to-study-efferocytosis 2024-09-21T04:25:39+00:00 weekly 0.7 https://trial.medpath.com/news/rethinking-beta-blocker-use-following-acute-myocardial-infarction 2024-09-21T03:17:28+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-investigational-new-drug-application-for-cd-001-in-oncology 2024-09-21T02:50:46+00:00 weekly 0.7 https://trial.medpath.com/news/a-precision-medicine-initiative-sponsored-by-the-national-cancer-institute-aims-to-improve 2024-09-21T02:43:57+00:00 weekly 0.7 https://trial.medpath.com/news/ibcn-2024-elucidating-the-response-rates-to-additional-bcg-implications-for-clinical-trial-design 2024-09-21T02:33:50+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-misses-end-of-summer-goal-for-phase-3-study-start-green-market-report 2024-09-21T02:25:26+00:00 weekly 0.7 https://trial.medpath.com/news/on-the-move-dr-michael-lyons-upstate-business-journal 2024-09-21T00:15:42+00:00 weekly 0.7 https://trial.medpath.com/news/novo-s-phase-ii-miss-in-obesity-oral-amps-up-pressure-on-bd-biocentury 2024-09-21T00:05:21+00:00 weekly 0.7 https://trial.medpath.com/news/actinium-pharmaceuticals-announces-publication-of-results-from-the-phase-3-sierra-trial 2024-09-20T23:59:02+00:00 weekly 0.7 https://trial.medpath.com/news/revolutionizing-oncology-insights-on-the-fda-s-project-optimus-and-dose-optimization 2024-09-20T23:40:32+00:00 weekly 0.7 https://trial.medpath.com/news/stereotactic-vs-hypofractionated-radiotherapy-for-inoperable-stage-i-non-small-cell-lung-cancer 2024-09-20T22:48:36+00:00 weekly 0.7 https://trial.medpath.com/news/new-cancer-research-breakthrough-has-the-potential-to-save-lives-nbc-boston 2024-09-20T22:38:15+00:00 weekly 0.7 https://trial.medpath.com/news/director-gagnon-robert-e-sold-365-worth-of-shares-131-units-at-2-79-decreasing-direct 2024-09-20T22:18:46+00:00 weekly 0.7 https://trial.medpath.com/news/ibcn-2024-a-randomized-phase-ii-trial-comparing-single-dose-perioperative-instillation 2024-09-20T21:53:26+00:00 weekly 0.7 https://trial.medpath.com/news/maeve-lowery-md-on-a-novel-bifunctional-antibody-in-advanced-hepatocellular-carcinoma 2024-09-20T21:47:27+00:00 weekly 0.7 https://trial.medpath.com/news/extended-estrogen-suppression-safe-in-breast-cancer-inside-precision-medicine 2024-09-20T21:30:55+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-cuts-radiation-time-dramatically-sanford-health-news 2024-09-20T21:25:44+00:00 weekly 0.7 https://trial.medpath.com/news/rock-you-like-a-migraine-opdp-issues-notice-of-violation-for-misleading-representations 2024-09-20T21:06:16+00:00 weekly 0.7 https://trial.medpath.com/news/this-week-at-fda-asca-guidances-new-clinical-trial-guidances-and-more-raps 2024-09-20T20:54:08+00:00 weekly 0.7 https://trial.medpath.com/news/after-july-surge-fda-approvals-for-gi-settle-into-summer-lull-what-you-may-have-missed 2024-09-20T20:42:17+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-straight-move-to-phase-3-ted-studies-makes-it-must-watch-nasdaq-slrn 2024-09-20T20:40:38+00:00 weekly 0.7 https://trial.medpath.com/news/me-therapeutics-to-begin-testing-of-first-mrna-formulations-from-nanovation-pharmabiz-com 2024-09-20T20:29:20+00:00 weekly 0.7 https://trial.medpath.com/news/tectonic-therapeutic-reports-findings-from-phase-ia-trial-of-tx45 2024-09-20T20:24:45+00:00 weekly 0.7 https://trial.medpath.com/news/stanford-car-t-solid-tumor-study-enrolls-first-pediatric-patient 2024-09-20T20:22:30+00:00 weekly 0.7 https://trial.medpath.com/news/promising-results-from-phase-1-2-trial-of-nkt2152-for-advanced-kidney-cancer 2024-09-20T20:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/nervgen-pharma-to-present-at-the-unite-2-fight-paralysis-19th-annual-science-advocacy 2024-09-20T20:02:28+00:00 weekly 0.7 https://trial.medpath.com/news/fibrobiologics-engages-southern-star-research-as-cro-in-australia-biospace 2024-09-20T20:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/ipsen-s-iqirvo-r-elafibranor-approved-in-the-european-union-as-first-new-treatment-for 2024-09-20T19:31:21+00:00 weekly 0.7 https://trial.medpath.com/news/cetylpyridinium-chloride-inhibits-hepatocellular-carcinoma-growth-and-metastasis-through-plos 2024-09-20T17:58:55+00:00 weekly 0.7 https://trial.medpath.com/news/eqs-adhoc-brain-biotech-ag-concludes-royalty-monetization-deal-for-up-to-eur-128-88 2024-09-20T17:53:07+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-nasal-spray-as-first-self-administered-flu-vaccine-healio 2024-09-20T17:22:29+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-approves-zevra-s-genetic-disorder-treatment-yahoo-finance 2024-09-20T17:16:41+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-and-corbus-pharmaceutical-stocks-plummet-benzinga-benzinga 2024-09-20T17:15:06+00:00 weekly 0.7 https://trial.medpath.com/news/ema-announces-positive-opinion-for-sb15-opuviz-samsung-bioepis-and-biogen 2024-09-20T16:57:09+00:00 weekly 0.7 https://trial.medpath.com/news/astellas-receives-approval-from-the-european-commission-for-vyloytm-zolbetuximab-in 2024-09-20T16:54:56+00:00 weekly 0.7 https://trial.medpath.com/news/intravascular-lithotripsy-a-clinical-trial-snapshot 2024-09-20T16:42:51+00:00 weekly 0.7 https://trial.medpath.com/news/fda-alert-pulmonology-drug-approvals-and-recalls-medical-device-updates 2024-09-20T16:41:53+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-tolebrutinib-demonstrated-a-31-delay-in-time-to-onset-of-confirmed-sanofi 2024-09-20T16:32:13+00:00 weekly 0.7 https://trial.medpath.com/news/ecu-health-pioneers-with-fda-approved-elupro-bioenvelope-in-pacemaker-implantation 2024-09-20T15:48:05+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-s-1bn-oral-weight-loss-drug-shows-promise-but-raises-questions-in-phase-iia-trial 2024-09-20T15:34:42+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-s-monlunabant-expectations-dashed-by-phase-ii-data-scrip-citeline 2024-09-20T15:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-mogwai-trial-to-test-azathioprine-as-first-line-treatment-for-mogad 2024-09-20T15:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-cabinet-trial-cabozantinib-in-advanced-neuroendocrine-tumors 2024-09-20T15:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/initial-in-vivo-validation-of-novel-cancer-therapeutics-using-ai-drug-target-review 2024-09-20T15:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/rx-rundown-maxcyte-roche-and-more-medical-marketing-and-media 2024-09-20T14:44:34+00:00 weekly 0.7 https://trial.medpath.com/news/henlius-biotech-s-drug-nears-eu-approval-tipranks-com 2024-09-20T14:43:28+00:00 weekly 0.7 https://trial.medpath.com/news/inavolisib-shows-promising-disease-control-rates-safety-in-patients-with-pik3ca-mutated 2024-09-20T14:36:36+00:00 weekly 0.7 https://trial.medpath.com/news/new-listings-in-avma-veterinary-clinical-trials-registry-september-2024 2024-09-20T14:34:17+00:00 weekly 0.7 https://trial.medpath.com/news/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp-16-19 2024-09-20T14:33:39+00:00 weekly 0.7 https://trial.medpath.com/news/apellis-eye-drug-again-turned-back-in-europe-biopharma-dive 2024-09-20T14:28:26+00:00 weekly 0.7 https://trial.medpath.com/news/an-optimized-strategy-triggered-at-the-2nd-immunization-visit-to-prevent-hiv-acquisition-by 2024-09-20T14:28:21+00:00 weekly 0.7 https://trial.medpath.com/news/aligos-reports-positive-data-from-phase-iia-mash-treatment-trial 2024-09-20T14:25:18+00:00 weekly 0.7 https://trial.medpath.com/news/targeted-therapies-novel-antibodies-and-immunotherapies-in-advanced-non-small-cell 2024-09-20T14:19:52+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-as-common-drug-shrinks-fatal-and-aggressive-brain-tumours-raising-hopes-of-a-cure 2024-09-20T14:17:13+00:00 weekly 0.7 https://trial.medpath.com/news/novo-s-next-gen-cb1-drug-leads-to-weight-loss-in-phase-ii-but-neuropsychiatric-events-reported 2024-09-20T14:11:36+00:00 weekly 0.7 https://trial.medpath.com/news/atezolizumab-venetoclax-and-obinutuzumab-in-richter-transformation-diffuse-large-b 2024-09-20T14:02:46+00:00 weekly 0.7 https://trial.medpath.com/news/revolution-or-mirage-controversy-surrounds-new-alzheimer-s-drugs-medical-xpress 2024-09-20T13:12:07+00:00 weekly 0.7 https://trial.medpath.com/news/darzalex-r-daratumumab-based-quadruplet-regimen-receives-positive-chmp-opinion-for 2024-09-20T13:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/novel-btk-inhibitor-lp-168-under-investigation-in-china-for-r-r-mantle-cell-lymphoma 2024-09-20T13:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/alpha-tau-announces-fda-approval-of-ide-to-initiate-multi-center-investigator-morningstar 2024-09-20T12:56:13+00:00 weekly 0.7 https://trial.medpath.com/news/where-will-amgen-be-in-5-years-aol-com 2024-09-20T12:49:11+00:00 weekly 0.7 https://trial.medpath.com/news/biosyngen-best-in-class-next-generation-tumor-infiltrating-lymphocyte-til-technology 2024-09-20T12:32:26+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-dupixent-recommended-for-eu-approval-by-the-chmp-to-treat-eosinophilic-sanofi 2024-09-20T12:06:28+00:00 weekly 0.7 https://trial.medpath.com/news/kangpu-completed-bridging-clinical-study-of-kpg-818-in-china-pr-newswire 2024-09-20T12:02:23+00:00 weekly 0.7 https://trial.medpath.com/news/marinus-pharmaceuticals-to-highlight-clinical-progress-and-commercial-launch-stock-titan 2024-09-20T12:01:20+00:00 weekly 0.7 https://trial.medpath.com/news/merck-receives-positive-eu-chmp-opinions-for-keytruda-r-pembrolizumab-regimens 2024-09-20T11:36:14+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-receives-positive-chmp-opinion-for-mirvetuximab-soravtansine-elahere-r-for 2024-09-20T11:34:51+00:00 weekly 0.7 https://trial.medpath.com/news/apellis-receives-negative-chmp-opinion-for-pegcetacoplan-for-geographic-atrophy-ga-in 2024-09-20T11:26:55+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-lse-azn-gains-fda-approval-for-fasenra-in-egpa-boosting-revenue 2024-09-20T10:47:22+00:00 weekly 0.7 https://trial.medpath.com/news/syncona-s-beacon-therapeutics-presents-trial-results-at-conference-morningstar 2024-09-20T10:10:23+00:00 weekly 0.7 https://trial.medpath.com/news/gprc5d-emerges-as-promising-target-in-multiple-myeloma-clinical-trials 2024-09-20T09:48:02+00:00 weekly 0.7 https://trial.medpath.com/news/dad-s-epilepsy-med-use-won-t-harm-his-kids-study 2024-09-20T09:28:01+00:00 weekly 0.7 https://trial.medpath.com/news/novel-strategies-emerge-to-transform-cold-tumors-into-immunotherapy-responsive-hot-tumors 2024-09-20T09:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/cspc-pharmaceutical-s-new-hypertension-drug-trials-approved-tipranks-com 2024-09-20T09:16:05+00:00 weekly 0.7 https://trial.medpath.com/news/yoga-other-exercise-can-curb-urinary-incontinence-in-women 2024-09-20T09:09:50+00:00 weekly 0.7 https://trial.medpath.com/news/are-antidepressants-being-overused-to-treat-seniors-pain 2024-09-20T09:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/caring-for-horses-could-help-veterans-battling-ptsd 2024-09-20T09:09:04+00:00 weekly 0.7 https://trial.medpath.com/news/dad-s-epilepsy-med-valproate-use-won-t-harm-his-kids-study 2024-09-20T09:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/european-ai-healthcare-startups-drive-medical-innovation-with-advanced-analytics-and-clinical-trial-solutions 2024-09-20T09:07:48+00:00 weekly 0.7 https://trial.medpath.com/news/gc-therapeutics-raises-65m-to-accelerate-revolutionary-ipsc-cell-programming-platform 2024-09-20T08:42:38+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-to-launch-palivizumab-synagis-in-india-express-pharma 2024-09-20T08:04:39+00:00 weekly 0.7 https://trial.medpath.com/news/recent-breakthroughs-in-cancer-research-could-impact-these-key-companies 2024-09-20T07:50:57+00:00 weekly 0.7 https://trial.medpath.com/news/ai-language-model-achieves-87-accuracy-in-distinguishing-fibromyalgia-from-other-chronic-pain-conditions 2024-09-20T07:00:01+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-announces-positive-results-from-global-phase-3-clinical-trial-of-izokibep 2024-09-20T06:42:01+00:00 weekly 0.7 https://trial.medpath.com/news/new-treatment-strategies-emerge-for-managing-car-t-cell-therapy-side-effects 2024-09-20T05:55:07+00:00 weekly 0.7 https://trial.medpath.com/news/wockhardt-targets-global-launch-of-new-meningitis-drug-with-6-bn-market-potential-by-2026 2024-09-20T05:38:53+00:00 weekly 0.7 https://trial.medpath.com/news/dr-paulo-fontoura-md-phd-joins-stalicla-as-chief-scientific-and-clinical-development-advisor 2024-09-20T05:10:36+00:00 weekly 0.7 https://trial.medpath.com/news/hemophilia-b-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-09-20T04:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/adrenoleukodystrophy-clinical-trials-2024-ema-pdma-fda-openpr-com 2024-09-20T03:34:01+00:00 weekly 0.7 https://trial.medpath.com/news/hitting-psoriatic-arthritis-early-with-apremilast-helps-some-patients-trial-finds 2024-09-20T03:13:19+00:00 weekly 0.7 https://trial.medpath.com/news/mesoblast-meso-biotechnology-innovator-nearing-critical-milestones-for-life-changing-therapies 2024-09-20T03:07:01+00:00 weekly 0.7 https://trial.medpath.com/news/pelareorep-plus-paclitaxel-extends-survival-in-hr-her2-breast-cancer 2024-09-20T02:26:16+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-biomarkers-that-predict-disability-worsening-in-multiple-sclerosis 2024-09-20T02:23:25+00:00 weekly 0.7 https://trial.medpath.com/news/euro-roundup-ema-finalizes-reflection-paper-on-establishing-efficacy-based-on-single-arm-trials 2024-09-20T01:44:59+00:00 weekly 0.7 https://trial.medpath.com/news/roche-reports-positive-data-from-phase-iii-influenza-treatment-trial 2024-09-20T01:42:57+00:00 weekly 0.7 https://trial.medpath.com/news/five-strategic-travel-solutions-to-boost-clinical-trial-diversity-and-patient-enrollment 2024-09-20T01:34:46+00:00 weekly 0.7 https://trial.medpath.com/news/rice-and-baylor-receive-2-8-million-to-suppress-inflammation-and-lung-damage 2024-09-20T00:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/checkmate-9er-post-hoc-analysis-seeks-to-identify-efficacy-biomarkers-for-nivolumab-onclive 2024-09-20T00:08:22+00:00 weekly 0.7 https://trial.medpath.com/news/immix-biopharma-stock-hits-52-week-low-at-1-74-amid-market-challenges-by-investing-com 2024-09-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kiromic-biopharma-activates-the-university-of-arizona-cancer-center-as-the-fifth-clinical 2024-09-19T23:27:34+00:00 weekly 0.7 https://trial.medpath.com/news/beacon-therapeutics-presents-36-month-interim-results-from-phase-i-2-horizon-trial-biospace 2024-09-19T23:27:32+00:00 weekly 0.7 https://trial.medpath.com/news/shaping-personalized-genetic-care-in-bc-ubc-faculty-of-medicine 2024-09-19T23:21:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-fast-track-designation-for-narmafotinib-in-advanced-pancreatic-cancer 2024-09-19T23:14:25+00:00 weekly 0.7 https://trial.medpath.com/news/asu-biochemist-honored-for-lifetime-achievement-in-improving-human-health 2024-09-19T22:17:12+00:00 weekly 0.7 https://trial.medpath.com/news/angiodynamics-initiates-recover-av-clinical-trial-assessing-alphavac-f1885-system-in 2024-09-19T22:15:35+00:00 weekly 0.7 https://trial.medpath.com/news/mantle-cell-lymphoma-clinical-trial-pipeline-insights-featuring-20-companies-delveinsight 2024-09-19T21:53:03+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-provides-corporate-update-on-upcoming-clinical-milestones-morningstar 2024-09-19T21:50:05+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-epitomee-an-ingestible-device-for-weight-management-neurology-advisor 2024-09-19T21:47:28+00:00 weekly 0.7 https://trial.medpath.com/news/genfit-reports-first-half-year-2024-financial-results-and-provides-corporate-update 2024-09-19T21:28:47+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-research-roundup-cancer-therapy-advisor 2024-09-19T21:10:37+00:00 weekly 0.7 https://trial.medpath.com/news/earlier-info-on-financial-stress-obesity-and-second-cancers-carcinogenic-condoms 2024-09-19T21:09:30+00:00 weekly 0.7 https://trial.medpath.com/news/regulatory-actions-for-sept-19-2024-bioworld 2024-09-19T20:48:13+00:00 weekly 0.7 https://trial.medpath.com/news/rezolute-reports-fourth-quarter-and-full-year-fiscal-2024-financial-results-and-provides 2024-09-19T20:14:06+00:00 weekly 0.7 https://trial.medpath.com/news/rogaratinib-plus-atezolizumab-in-cisplatin-ineligible-patients-with-fgfr-rna-jama-network 2024-09-19T20:03:23+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-a-s-wegovy-r-recommended-by-the-european-regulatory-authorities-for-label 2024-09-19T19:52:51+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-dosage-of-trastuzumab-biosimilar-for-her2-overexpressing-cancers 2024-09-19T19:31:24+00:00 weekly 0.7 https://trial.medpath.com/news/elanco-announces-fda-approval-and-launch-of-zenreliatm-ilunocitinib-tablets-offering-an 2024-09-19T19:21:32+00:00 weekly 0.7 https://trial.medpath.com/news/aplt-stock-soars-69-on-positive-update-on-galactosemia-drug-nda-yahoo-finance 2024-09-19T19:06:32+00:00 weekly 0.7 https://trial.medpath.com/news/top-in-women-s-health-fda-warning-for-fezolinetant-trauma-may-be-toxic-for-brain-health 2024-09-19T18:55:25+00:00 weekly 0.7 https://trial.medpath.com/news/bright-minds-biosciences-to-host-investor-analyst-kol-event-on-september-25th 2024-09-19T18:48:41+00:00 weekly 0.7 https://trial.medpath.com/news/recon-fda-rejects-vanda-s-stomach-condition-drug-eu-authorizes-bavarian-mpox-vaccine 2024-09-19T18:47:53+00:00 weekly 0.7 https://trial.medpath.com/news/dr-srinivas-on-the-role-of-lutetium-lu-177-vipivotide-tetraxetan-in-mcrpc-onclive 2024-09-19T18:46:03+00:00 weekly 0.7 https://trial.medpath.com/news/imvanex-opinion-on-variation-to-marketing-authorisation-european-medicines-agency 2024-09-19T18:43:41+00:00 weekly 0.7 https://trial.medpath.com/news/summit-therapeutics-bests-merck-s-top-selling-drug-in-phase-iii-trial-seeking-alpha 2024-09-19T18:40:04+00:00 weekly 0.7 https://trial.medpath.com/news/arterial-hypertension-clinical-trials-update-2024-nature 2024-09-19T18:25:36+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-could-move-the-needle-in-traumatic-brain-injury-uc-san-francisco 2024-09-19T18:02:01+00:00 weekly 0.7 https://trial.medpath.com/news/rintatolimod-plus-durvalumab-shows-early-disease-control-in-late-stage-pancreatic-cancer 2024-09-19T17:43:24+00:00 weekly 0.7 https://trial.medpath.com/news/unlv-and-global-alzheimer-s-organization-collaborating-to-bring-next-gen-research-to-las-vegas 2024-09-19T16:30:56+00:00 weekly 0.7 https://trial.medpath.com/news/rapid-normalization-of-vitamin-d-deficiency-in-picu-vitdalize-kids-trials-journal 2024-09-19T15:37:45+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-remark-trial-of-rvu120-doses-first-patient-with-lower-risk-mds 2024-09-19T15:33:10+00:00 weekly 0.7 https://trial.medpath.com/news/ema-recommends-extending-indication-of-mpox-vaccine-to-adolescents 2024-09-19T15:29:10+00:00 weekly 0.7 https://trial.medpath.com/news/certain-diabetes-drugs-may-lower-risk-of-dementia-and-parkinson-s-disease 2024-09-19T15:23:42+00:00 weekly 0.7 https://trial.medpath.com/news/pharmacosmos-completes-strategic-acquisition-of-g1-therapeutics-in-multi-million-dollar-deal 2024-09-19T15:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-declines-to-approve-vanda-s-marketing-application-for-tradipitant-in-gastroparesis 2024-09-19T15:18:19+00:00 weekly 0.7 https://trial.medpath.com/news/mpox-three-ongoing-vaccine-trials-to-watch-clinical-trials-arena 2024-09-19T15:16:08+00:00 weekly 0.7 https://trial.medpath.com/news/trial-supports-uninterrupted-use-of-imatinib-for-gist-nci 2024-09-19T15:15:51+00:00 weekly 0.7 https://trial.medpath.com/news/comparative-effects-of-drug-interventions-for-the-acute-management-of-migraine-episodes-in-adults 2024-09-19T15:14:09+00:00 weekly 0.7 https://trial.medpath.com/news/overall-survival-with-cabozantinib-vs-sunitinib-in-advanced-papillary-renal-cell-carcinoma 2024-09-19T15:09:35+00:00 weekly 0.7 https://trial.medpath.com/news/chip-and-mcas-linked-to-risk-of-cancer-death-hematology-advisor 2024-09-19T15:01:52+00:00 weekly 0.7 https://trial.medpath.com/news/university-of-hong-kong-opens-first-clinical-trials-centre-with-private-hospital-cancer-a-focus 2024-09-19T15:00:11+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-clinical-trials-a-new-approach-to-treating-cancer-yahoo-finance 2024-09-19T14:37:32+00:00 weekly 0.7 https://trial.medpath.com/news/non-invasive-method-can-help-predict-survival-in-patients-with-liver-cancer-medical-xpress 2024-09-19T14:32:17+00:00 weekly 0.7 https://trial.medpath.com/news/bavarian-nordic-gets-ema-approval-of-mpox-vaccine-for-adolescents-proinvestor 2024-09-19T14:22:34+00:00 weekly 0.7 https://trial.medpath.com/news/22q11-2-deletion-syndrome-pipeline-market-research-report-2024-yahoo-finance 2024-09-19T14:19:51+00:00 weekly 0.7 https://trial.medpath.com/news/imac-holdings-inc-launches-subsidiary-ignite-proteomics-and-announces-groundbreaking 2024-09-19T14:10:14+00:00 weekly 0.7 https://trial.medpath.com/news/anticipated-cancer-antibody-drug-conjugates-fda-approval-by-2027-biospace 2024-09-19T13:52:43+00:00 weekly 0.7 https://trial.medpath.com/news/traveler-s-diarrhea-therapeutics-pipeline-market-report-2024-featuring-immuron 2024-09-19T13:49:20+00:00 weekly 0.7 https://trial.medpath.com/news/starton-successfully-delivers-cancer-drug-using-on-body-injector-clinical-trials-arena 2024-09-19T13:44:44+00:00 weekly 0.7 https://trial.medpath.com/news/newron-presents-h1-2024-results-and-provides-business-update-morningstar 2024-09-19T13:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/mda-awards-500000-grant-to-accelerate-als-research-globenewswire 2024-09-19T13:25:02+00:00 weekly 0.7 https://trial.medpath.com/news/apnimed-announces-early-completion-of-enrollment-in-phase-3-synairgy-study-of-ad109 2024-09-19T13:16:58+00:00 weekly 0.7 https://trial.medpath.com/news/covid-may-trigger-chronic-fatigue-syndrome-kaiser-permanente-division-of-research 2024-09-19T13:08:19+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-announces-start-of-recruitment-in-two-new-phase-iii-trials-evaluating-saphnelo 2024-09-19T13:07:58+00:00 weekly 0.7 https://trial.medpath.com/news/pharmacogenomics-pioneer-to-lead-first-multinational-study-university-world-news 2024-09-19T13:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/edgewise-therapeutics-announces-positive-top-line-data-from-phase-1-trial-in-healthy 2024-09-19T12:50:25+00:00 weekly 0.7 https://trial.medpath.com/news/biosyngen-presents-pioneering-conditional-activation-armor-enhancement-super-t 2024-09-19T12:47:24+00:00 weekly 0.7 https://trial.medpath.com/news/longboard-pharmaceuticals-receives-rare-pediatric-disease-designation-and-stock-titan 2024-09-19T12:39:06+00:00 weekly 0.7 https://trial.medpath.com/news/oric-pharmaceuticals-maintains-buy-rating-amidst-competitive-landscape 2024-09-19T12:23:07+00:00 weekly 0.7 https://trial.medpath.com/news/novel-ar-degraders-and-emerging-therapies-show-promise-in-advanced-prostate-cancer-treatment 2024-09-19T12:22:27+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-builds-combo-case-for-rsv-shingles-shots-with-phase-iii-data-biospace 2024-09-19T12:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/takeda-to-present-additional-clinical-trial-study-data-highlighting-the-impact-of-orexin 2024-09-19T12:06:36+00:00 weekly 0.7 https://trial.medpath.com/news/kiromic-biopharma-advances-deltacel-01-into-expansion-phase-following-safety 2024-09-19T12:05:24+00:00 weekly 0.7 https://trial.medpath.com/news/quralis-announces-expansion-of-its-selective-kv7-2-7-3-ion-channel-opener-qrl-101-into-epilepsy 2024-09-19T11:48:08+00:00 weekly 0.7 https://trial.medpath.com/news/skb264-innovative-cancer-antibody-drug-conjugate-clinical-trials-efficacy-insight 2024-09-19T11:47:02+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-study-shows-viability-of-177lu-psma-617-for-taxane-naive-metastatic-castration 2024-09-19T11:21:06+00:00 weekly 0.7 https://trial.medpath.com/news/xspray-pharma-announces-positive-fda-meeting-and-plans-for-dasynoc-nda-resubmission 2024-09-19T11:16:42+00:00 weekly 0.7 https://trial.medpath.com/news/irinotecan-hydrochloride-liposome-hr070803-in-combination-with-5-fluorouracil-and-nature 2024-09-19T11:07:57+00:00 weekly 0.7 https://trial.medpath.com/news/trastuzumab-biosimilar-and-pertuzumab-effective-safe-in-neoadjuvant-breast-cancer-therapy 2024-09-19T11:06:26+00:00 weekly 0.7 https://trial.medpath.com/news/carematrix-launches-blinded-remote-monitoring-tech-for-clinical-trials 2024-09-19T10:35:32+00:00 weekly 0.7 https://trial.medpath.com/news/nurabio-closes-140m-fundraising-to-develop-neuroprotective-drugs 2024-09-19T10:33:47+00:00 weekly 0.7 https://trial.medpath.com/news/lecanemab-s-benefits-are-too-small-and-uncertain-the-bmj 2024-09-19T09:54:51+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-s-nubeqa-breakthrough-in-prostate-cancer-with-46-risk-reduction-and-future 2024-09-19T09:50:43+00:00 weekly 0.7 https://trial.medpath.com/news/elacestrant-plus-abemaciclib-demonstrates-clinical-benefit-in-pretreated-er-her2-onclive 2024-09-19T09:45:24+00:00 weekly 0.7 https://trial.medpath.com/news/effectiveness-of-long-term-low-dose-aspirin-in-the-prevention-of-gastric-cancer-after 2024-09-19T09:42:24+00:00 weekly 0.7 https://trial.medpath.com/news/we-are-funding-hope-montreal-children-s-hospital-gets-a-boost-for-cancer-clinical-trials 2024-09-19T09:25:22+00:00 weekly 0.7 https://trial.medpath.com/news/biopharma-services-announces-expansion-into-late-stage-patient-trials-and-integration 2024-09-19T07:30:53+00:00 weekly 0.7 https://trial.medpath.com/news/global-superbug-crisis-amr-deaths-projected-to-reach-39-million-by-2050-lancet-study-warns 2024-09-19T07:01:20+00:00 weekly 0.7 https://trial.medpath.com/news/positive-pre-clinical-result-drive-to-human-trials-company-announcement-investegate 2024-09-19T06:03:28+00:00 weekly 0.7 https://trial.medpath.com/news/egetis-submits-a-patent-application-to-the-united-states-patent-and-trademark-office-for 2024-09-19T05:12:06+00:00 weekly 0.7 https://trial.medpath.com/news/flatiron-health-expands-its-mission-to-make-trials-more-pragmatic 2024-09-19T05:00:04+00:00 weekly 0.7 https://trial.medpath.com/news/lupin-partners-with-takeda-to-launch-novel-acid-blocker-vonoprazan-in-india 2024-09-19T02:21:05+00:00 weekly 0.7 https://trial.medpath.com/news/three-major-trends-reshaping-precision-medicine-ai-crispr-and-mrna-technologies-lead-innovation 2024-09-19T00:39:05+00:00 weekly 0.7 https://trial.medpath.com/news/transcenta-updates-encouraging-efficacy-data-from-first-line-triple-combo-trial-of-pr-newswire 2024-09-19T00:11:33+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-at-sidra-medicine-offers-hope-to-children-with-rare-diseases 2024-09-19T00:02:19+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-no-short-term-benefit-of-adding-revascularization-to-medical-therapy-for-carotid-stenosis 2024-09-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sprc-scisparc-ltd-ordinary-shares-latest-stock-news-market-updates 2024-09-18T23:54:58+00:00 weekly 0.7 https://trial.medpath.com/news/organon-gets-more-skin-in-the-game-by-acquiring-roivant-s-dermatology-subsidiary 2024-09-18T23:30:39+00:00 weekly 0.7 https://trial.medpath.com/news/reactivating-interest-in-hsv-shedding-after-solid-organ-transplant-fred-hutchinson-cancer-center 2024-09-18T22:50:04+00:00 weekly 0.7 https://trial.medpath.com/news/improving-car-t-cell-efficacy-via-new-manufacturing-process 2024-09-18T22:25:54+00:00 weekly 0.7 https://trial.medpath.com/news/applied-therapeutics-provides-regulatory-update-on-govorestat-for-the-treatment-of-classic-galactosemia 2024-09-18T22:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/new-briumvi-r-ublituximab-xiiy-data-from-the-enhance-phase-3b-study-show-rapid-30 2024-09-18T21:57:15+00:00 weekly 0.7 https://trial.medpath.com/news/applied-therapeutics-provides-regulatory-update-on-govorestat-for-the-treatment-of-biospace 2024-09-18T21:57:11+00:00 weekly 0.7 https://trial.medpath.com/news/bone-marrow-cancer-drug-shows-success-in-treatment-of-rare-blood-disorder 2024-09-18T21:22:58+00:00 weekly 0.7 https://trial.medpath.com/news/lenvatinib-combo-yields-substantial-antitumor-activity-in-endometrial-cancer 2024-09-18T21:11:38+00:00 weekly 0.7 https://trial.medpath.com/news/4dmt-shares-data-from-phase-1-2-prism-clinical-trial-4front-phase-3-study-design 2024-09-18T21:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-palliative-radiotherapy-to-best-supportive-care-in-painful-hepatic-cancer 2024-09-18T20:52:41+00:00 weekly 0.7 https://trial.medpath.com/news/new-study-challenges-amyloid-beta-theory-on-cause-for-alzheimer-s-disease 2024-09-18T20:38:35+00:00 weekly 0.7 https://trial.medpath.com/news/park-and-patel-explore-advances-in-egfr-nsclc-from-asco-2024-onclive 2024-09-18T20:27:40+00:00 weekly 0.7 https://trial.medpath.com/news/phelps-health-offers-inspire-therapy-for-obstructive-sleep-apnea-news-phelpscountyfocus-com 2024-09-18T20:26:13+00:00 weekly 0.7 https://trial.medpath.com/news/ossium-treats-first-leukaemia-patient-in-cryopreserved-bone-marrow-trial 2024-09-18T20:20:28+00:00 weekly 0.7 https://trial.medpath.com/news/vivos-therapeutics-says-it-is-poised-to-disrupt-pediatric-sleep-apnea-market-secures-fda 2024-09-18T20:20:04+00:00 weekly 0.7 https://trial.medpath.com/news/medicaid-might-help-increase-clinical-trial-diversity-penn-ldi 2024-09-18T20:18:11+00:00 weekly 0.7 https://trial.medpath.com/news/scisparc-takes-major-step-forward-with-ind-application-submitted-to-the-fda-for-phase-iib 2024-09-18T20:17:52+00:00 weekly 0.7 https://trial.medpath.com/news/fewer-cancer-drugs-exempt-from-pediatric-testing-after-race-act-healio 2024-09-18T20:10:54+00:00 weekly 0.7 https://trial.medpath.com/news/exploring-advancements-in-higher-risk-mds-targeted-oncology 2024-09-18T20:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/new-trial-to-test-potential-treatment-for-chronic-kidney-disease-university-of-oxford 2024-09-18T19:55:04+00:00 weekly 0.7 https://trial.medpath.com/news/personalized-treatment-could-be-key-to-tackling-uncontrolled-high-blood-pressure 2024-09-18T19:54:04+00:00 weekly 0.7 https://trial.medpath.com/news/aclaris-doses-first-subject-in-phase-iia-atopic-dermatitis-treatment-trial 2024-09-18T19:37:38+00:00 weekly 0.7 https://trial.medpath.com/news/implantica-s-anti-reflux-device-shows-positive-two-year-results-clinical-trials-arena 2024-09-18T19:37:38+00:00 weekly 0.7 https://trial.medpath.com/news/medical-breakthrough-new-drug-being-tested-to-help-treat-strokes-krgv 2024-09-18T19:09:29+00:00 weekly 0.7 https://trial.medpath.com/news/alteogen-seeks-approval-for-aflibercept-biosimilar-in-korea-goodwin-jdsupra 2024-09-18T18:38:15+00:00 weekly 0.7 https://trial.medpath.com/news/sunrise-4-neoadjuvant-tar-200-cetrelimab-is-linked-with-strong-pcr-por-in-mibc 2024-09-18T18:18:11+00:00 weekly 0.7 https://trial.medpath.com/news/oral-geographic-atrophy-treatment-misses-primary-endpoint-in-phase-3-study-healio 2024-09-18T17:18:10+00:00 weekly 0.7 https://trial.medpath.com/news/plaquetec-and-rxcelerate-collaborate-on-early-phase-drug-discovery-for-coronary-artery-disease 2024-09-18T17:18:01+00:00 weekly 0.7 https://trial.medpath.com/news/dr-toni-choueiri-on-key-takeaways-from-tinivo-2-trial-urology-times 2024-09-18T17:15:27+00:00 weekly 0.7 https://trial.medpath.com/news/kesimpta-shows-promise-in-reducing-relapsing-multiple-sclerosis-disability-progression 2024-09-18T16:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-cf33-hnis-for-cholangiocarcinoma-onclive 2024-09-18T16:34:07+00:00 weekly 0.7 https://trial.medpath.com/news/usc-launches-study-on-how-type-1-diabetes-affects-childhood-brain-development 2024-09-18T16:15:55+00:00 weekly 0.7 https://trial.medpath.com/news/nih-led-studies-point-to-potential-development-of-a-cataract-drug 2024-09-18T15:23:59+00:00 weekly 0.7 https://trial.medpath.com/news/io-therapeutics-inc-presented-data-from-studies-of-irx4204-the-company-s-phase-ii-morningstar 2024-09-18T15:17:18+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-data-show-durvalumab-improves-overall-survival-event-free-survival-pharmacy-times 2024-09-18T15:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/dato-dxd-demonstrates-efficacy-safety-in-platinum-resistant-ovarian-and-endometrial-cancers 2024-09-18T14:42:30+00:00 weekly 0.7 https://trial.medpath.com/news/it-s-past-time-to-end-hiv-wonder-drug-experimentation-in-africa-stat-news 2024-09-18T14:33:42+00:00 weekly 0.7 https://trial.medpath.com/news/kaida-biopharma-launches-social-media-channels-morningstar 2024-09-18T14:18:29+00:00 weekly 0.7 https://trial.medpath.com/news/research-study-participants-are-more-engaged-when-they-see-their-test-results-uic-today 2024-09-18T14:06:26+00:00 weekly 0.7 https://trial.medpath.com/news/glycomine-receives-fda-fast-track-designation-for-glm101-for-the-treatment-of-pmm2-cdg 2024-09-18T13:49:02+00:00 weekly 0.7 https://trial.medpath.com/news/azitra-receives-fast-track-designation-for-atr-04-for-skin-rash-from-egfr-inhibitors 2024-09-18T13:37:05+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-teases-positive-data-adaptive-deep-brain-stimulation-trial 2024-09-18T13:35:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-partial-clinical-hold-on-vigil-neuroscience-s-phase-i-vg-3927-trial 2024-09-18T13:35:41+00:00 weekly 0.7 https://trial.medpath.com/news/insilico-medicine-reports-positive-phase-iia-results-for-ism001-055-a-novel-first-in-class 2024-09-18T13:30:27+00:00 weekly 0.7 https://trial.medpath.com/news/tap-into-the-a4-study-for-unprecedented-alzheimer-s-clinical-trial-data 2024-09-18T13:23:47+00:00 weekly 0.7 https://trial.medpath.com/news/praxis-precision-s-relutrigine-reduces-seizures-in-rare-epileptic-disorders-in-phase-2-clinical-trials 2024-09-18T12:59:14+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-starts-new-phase-iii-study-with-wegovy-successor-medwatch 2024-09-18T12:46:40+00:00 weekly 0.7 https://trial.medpath.com/news/plus-therapeutics-showcases-new-interim-respect-gbm-phase-2-trial-data-at-the-2024 2024-09-18T12:15:01+00:00 weekly 0.7 https://trial.medpath.com/news/briacell-announces-fda-authorized-expanded-access-policy-for-metastatic-breast-cancer-patients 2024-09-18T12:09:37+00:00 weekly 0.7 https://trial.medpath.com/news/new-data-to-be-presented-from-eftisarc-neo-phase-ii-globenewswire 2024-09-18T12:07:40+00:00 weekly 0.7 https://trial.medpath.com/news/accord-biopharma-inc-announces-u-s-food-drug-administration-approval-of-420mg 2024-09-18T12:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/biosyngen-s-first-in-class-car-t-asset-targeting-solid-tumors-has-entered-pivotal-phase-ii 2024-09-18T11:31:06+00:00 weekly 0.7 https://trial.medpath.com/news/mira-pharmaceuticals-advances-ketamir-2-development-following-phase-1-design 2024-09-18T11:25:29+00:00 weekly 0.7 https://trial.medpath.com/news/satellos-announces-dosing-of-first-participant-in-phase-1-clinical-study-of-sat-3247 2024-09-18T11:22:22+00:00 weekly 0.7 https://trial.medpath.com/news/planned-for-a-marathon-but-it-turned-into-a-sprint-a-blog-by-tunde-oremule-ent-registrar 2024-09-18T11:14:24+00:00 weekly 0.7 https://trial.medpath.com/news/alk-renal-cell-carcinoma-case-study-demonstrates-success-of-precision-medicine-approach 2024-09-18T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mannkind-announces-clearance-from-pmda-to-initiate-phase-3-clinical-trial-icon-1-biospace 2024-09-18T10:47:41+00:00 weekly 0.7 https://trial.medpath.com/news/invion-s-inv043-candidate-demonstrates-positive-results-in-phase-ii-prostate-cancer-trial 2024-09-18T09:56:15+00:00 weekly 0.7 https://trial.medpath.com/news/most-promising-new-drugs-for-hidradenitis-suppurativa-with-raj-chovatiya-md-phd 2024-09-18T09:33:28+00:00 weekly 0.7 https://trial.medpath.com/news/post-op-keytruda-boosts-bladder-cancer-outcomes 2024-09-18T09:09:10+00:00 weekly 0.7 https://trial.medpath.com/news/imcheck-receives-fda-fast-track-designation-for-ict01-in-globenewswire 2024-09-18T09:02:59+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-therapy-could-improve-outcomes-for-nasal-and-paranasal-sinus-cancer 2024-09-18T09:02:20+00:00 weekly 0.7 https://trial.medpath.com/news/merit-medical-touts-positive-six-month-data-from-wave-trial 2024-09-18T08:43:49+00:00 weekly 0.7 https://trial.medpath.com/news/nicox-announces-approval-of-zerviate-in-china-biospace 2024-09-18T08:31:13+00:00 weekly 0.7 https://trial.medpath.com/news/fasenra-egpa-us-fda-approval-astrazeneca-cision-news 2024-09-18T08:20:55+00:00 weekly 0.7 https://trial.medpath.com/news/sensorion-reports-2024-first-half-results-and-highlights-recent-updates-yahoo-finance 2024-09-18T06:58:36+00:00 weekly 0.7 https://trial.medpath.com/news/wclc-2024-study-reveals-multiple-hidden-burdens-of-lung-cancer-treatment-financial-time-and-sexual-health-impacts 2024-09-18T06:37:40+00:00 weekly 0.7 https://trial.medpath.com/news/poolbeg-pharma-patent-portfolio-significantly-strengthened-expanded 2024-09-18T06:35:53+00:00 weekly 0.7 https://trial.medpath.com/news/immunic-presents-key-vidofludimus-calcium-data-at-the-40th-congress-of-ectrims 2024-09-18T06:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/brenus-pharma-raises-25-million-to-accelerate-clinical-trials-of-its-precision-cancer-vaccines 2024-09-18T06:29:04+00:00 weekly 0.7 https://trial.medpath.com/news/fda-formalizes-protocol-for-international-cancer-trials-stat-news 2024-09-18T06:04:25+00:00 weekly 0.7 https://trial.medpath.com/news/valneva-seeks-approval-to-expand-ixchiq-chikungunya-vaccine-use-to-adolescents-in 2024-09-18T05:39:09+00:00 weekly 0.7 https://trial.medpath.com/news/baptist-health-achieves-52-reduction-in-high-risk-infusion-errors-through-system-wide-pump-standardization 2024-09-18T05:17:49+00:00 weekly 0.7 https://trial.medpath.com/news/lymphedema-risk-no-higher-with-3-week-rt-regimen-in-early-breast-cancer 2024-09-18T04:03:40+00:00 weekly 0.7 https://trial.medpath.com/news/autobahn-therapeutics-starts-trial-of-abx-002-for-major-depressive-disorder-in-adults 2024-09-18T03:43:14+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-nyse-lly-gains-fda-approval-for-ebglyss-expands-strategic-alliances-for 2024-09-18T02:08:49+00:00 weekly 0.7 https://trial.medpath.com/news/perioperative-durvalumab-reduced-risk-of-recurrence-or-death-vs-neoadjuvant-the-asco-post 2024-09-18T01:58:55+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-long-covid-an-investigator-initiated-trial-iit-with-hyundai-bioscience-s 2024-09-18T01:41:01+00:00 weekly 0.7 https://trial.medpath.com/news/novel-triplet-regimen-yields-promising-response-in-advanced-phase-chronic-myeloid-leukemia 2024-09-18T00:49:24+00:00 weekly 0.7 https://trial.medpath.com/news/fda-considers-revoking-pfizer-covid-19-vaccine-authorization-for-healthy-children-under-5 2024-09-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-initiates-two-phase-i-trials-testing-novel-therapies-for-advanced-solid-tumors-and-relapsed-refractory-lymphomas 2024-09-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/upfrontpsma-177lu-psma-617-shows-potential-in-mhspc-urology-times 2024-09-17T23:47:15+00:00 weekly 0.7 https://trial.medpath.com/news/ai-driven-saliva-test-revolutionizes-epilepsy-home-care-mirage-news 2024-09-17T23:24:43+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-pembrolizumab-chemo-in-unresectable-pleural-mesothelioma 2024-09-17T23:22:28+00:00 weekly 0.7 https://trial.medpath.com/news/cdmo-kincell-secures-partnership-to-manufacture-cell-therapy-for-clinical-trials 2024-09-17T23:22:16+00:00 weekly 0.7 https://trial.medpath.com/news/trishula-therapeutics-reports-results-from-phase-i-trial-of-pancreatic-cancer-drug 2024-09-17T22:55:08+00:00 weekly 0.7 https://trial.medpath.com/news/microbot-medical-announces-the-successful-enrollment-of-50-of-the-patients-in-its-pivotal 2024-09-17T22:36:55+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-s-new-drug-submission-for-omaveloxolone-accepted-for-priority-review-by-health 2024-09-17T22:36:54+00:00 weekly 0.7 https://trial.medpath.com/news/sysmex-inostics-ras-raf-seq-assay-receives-new-york-state-department-of-health 2024-09-17T22:36:53+00:00 weekly 0.7 https://trial.medpath.com/news/lisata-therapeutics-announces-first-patient-treated-in-the-second-line-biospace 2024-09-17T22:36:52+00:00 weekly 0.7 https://trial.medpath.com/news/q-a-ethical-decision-making-around-neurotechnology-treatments-penn-state-university 2024-09-17T22:18:44+00:00 weekly 0.7 https://trial.medpath.com/news/cms-new-breakthrough-device-policy-shows-little-promise-law360 2024-09-17T21:23:35+00:00 weekly 0.7 https://trial.medpath.com/news/dr-mehta-on-fda-approved-treatment-options-in-later-line-hematologic-malignancies 2024-09-17T21:21:05+00:00 weekly 0.7 https://trial.medpath.com/news/patients-at-last-begin-receiving-vertex-crispr-and-bluebird-sickle-cell-gene-therapies 2024-09-17T21:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-final-guidance-on-dcts-adds-clarity-on-hcp-task-log-inspection-requirements-data-variability 2024-09-17T21:09:18+00:00 weekly 0.7 https://trial.medpath.com/news/should-young-kids-take-the-new-anti-obesity-drugs-what-the-research-says-nature 2024-09-17T21:05:31+00:00 weekly 0.7 https://trial.medpath.com/news/keytruda-keys-in-on-survival-promising-results-in-high-risk-early-stage-tnbc-from-keynote-522 2024-09-17T20:41:25+00:00 weekly 0.7 https://trial.medpath.com/news/an-oral-benzothiophene-bdk-inhibitor-disclosed-by-pfizer 2024-09-17T20:36:22+00:00 weekly 0.7 https://trial.medpath.com/news/study-oncology-accelerated-approvals-are-often-based-on-non-comparative-trials-raps 2024-09-17T20:34:13+00:00 weekly 0.7 https://trial.medpath.com/news/elon-musk-s-neuralink-secures-fda-breakthrough-status-for-vision-implant 2024-09-17T20:26:41+00:00 weekly 0.7 https://trial.medpath.com/news/bubs-australia-asx-bub-one-of-the-few-infant-formula-stocks-building-a-post-china-future 2024-09-17T20:08:28+00:00 weekly 0.7 https://trial.medpath.com/news/senseonics-receives-fda-clearance-for-one-year-cgm-medtech-dive 2024-09-17T19:57:38+00:00 weekly 0.7 https://trial.medpath.com/news/metabolic-dysfunction-associated-steatohepatitis-mash-clinical-program-design 2024-09-17T19:45:59+00:00 weekly 0.7 https://trial.medpath.com/news/asv-is-not-a-generic-device-sleep-review 2024-09-17T19:45:46+00:00 weekly 0.7 https://trial.medpath.com/news/musk-s-neuralink-gets-fda-s-breakthrough-device-tag-for-blindsight-implant-cna 2024-09-17T19:41:18+00:00 weekly 0.7 https://trial.medpath.com/news/i-choose-to-climb-instead-of-fall-nih-medlineplus-magazine 2024-09-17T19:35:57+00:00 weekly 0.7 https://trial.medpath.com/news/quidelortho-receives-fda-approval-for-std-assay-san-diego-business-journal 2024-09-17T19:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/enhanced-cytosine-base-editing-for-duchenne-muscular-dystrophy-crispr-medicine 2024-09-17T18:55:34+00:00 weekly 0.7 https://trial.medpath.com/news/sparta-biomedical-reports-treatment-of-first-patients-with-breakthrough-device-ormi 2024-09-17T18:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/allclinicaltrials-com-empowering-patients-with-easy-access-to-clinical-trials-the-globe-and-mail 2024-09-17T18:28:21+00:00 weekly 0.7 https://trial.medpath.com/news/data-roundup-august-2024-features-updates-in-car-t-mrna-therapy-and-gamma 2024-09-17T18:14:49+00:00 weekly 0.7 https://trial.medpath.com/news/fred-saad-md-on-implications-of-phase-3-aranote-data-in-mhspc-urology-times 2024-09-17T18:08:43+00:00 weekly 0.7 https://trial.medpath.com/news/cms-finalizes-new-transitional-coverage-for-emerging-technologies-tcet-pathway-to 2024-09-17T18:07:09+00:00 weekly 0.7 https://trial.medpath.com/news/benmelstobart-plus-anlotinib-demonstrates-efficacy-in-frontline-advanced-rcc-onclive 2024-09-17T18:06:12+00:00 weekly 0.7 https://trial.medpath.com/news/iview-therapeutics-inc-completes-patient-recruitment-for-phase-1-2-trial-of-ivw-1001 2024-09-17T17:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/damaged-small-intestine-repaired-with-hpsc-derived-organoids-drug-target-review 2024-09-17T17:03:47+00:00 weekly 0.7 https://trial.medpath.com/news/patritumab-deruxtecan-demonstrated-statistically-significant-improvement-in-progression 2024-09-17T16:50:26+00:00 weekly 0.7 https://trial.medpath.com/news/leigh-s-lost-and-found-digital-extra-area-dogs-participate-in-study-to-extend-lives-ky3 2024-09-17T16:48:46+00:00 weekly 0.7 https://trial.medpath.com/news/canaccord-highlights-arcturus-stock-potential-amid-regulatory-wins-investing-com 2024-09-17T16:45:02+00:00 weekly 0.7 https://trial.medpath.com/news/medical-marijuana-users-see-short-term-gains-in-health-related-quality-of-life-study-finds 2024-09-17T16:44:06+00:00 weekly 0.7 https://trial.medpath.com/news/desai-sethi-research-team-identifies-how-to-reverse-the-genetics-of-poor-prostate-cancer 2024-09-17T16:17:58+00:00 weekly 0.7 https://trial.medpath.com/news/use-of-metformin-in-adults-with-diabetes-linked-to-lower-risk-of-long-covid 2024-09-17T16:16:18+00:00 weekly 0.7 https://trial.medpath.com/news/ev-pembrolizumab-yields-pfs-os-orr-benefits-regardless-of-nectin-4-level 2024-09-17T16:03:22+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-target-discovered-for-aggressive-prostate-cancer 2024-09-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-eli-lilly-brings-the-competition-to-novartis-with-new-results-in-mcrpc 2024-09-17T15:59:36+00:00 weekly 0.7 https://trial.medpath.com/news/tislelizumab-receives-israeli-approval-in-unresectable-or-metastatic-escc-onclive 2024-09-17T15:43:37+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-gets-the-first-phase-iii-hit-in-ipf-for-a-decade-scrip-citeline 2024-09-17T15:37:17+00:00 weekly 0.7 https://trial.medpath.com/news/obesity-pill-races-heats-up-as-novo-roche-and-terns-share-data-biospace 2024-09-17T15:23:11+00:00 weekly 0.7 https://trial.medpath.com/news/tomosynthesis-more-effective-than-mammography-for-breast-cancer-screening 2024-09-17T14:08:07+00:00 weekly 0.7 https://trial.medpath.com/news/survival-improves-with-atezolizumab-switch-therapy-in-braf-melanoma 2024-09-17T14:03:39+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-24-pfizer-to-take-cancer-weight-gain-drug-into-phase-iii-scrip-citeline 2024-09-17T14:03:06+00:00 weekly 0.7 https://trial.medpath.com/news/cps-technologies-corporation-announces-phase-ii-award-from-the-department-of-energy 2024-09-17T13:43:46+00:00 weekly 0.7 https://trial.medpath.com/news/inmune-bio-announces-results-of-additional-blinded-interim-analysis-of-phase-2-morningstar 2024-09-17T13:33:33+00:00 weekly 0.7 https://trial.medpath.com/news/immunos-therapeutics-ag-raises-us-11m-in-series-c-financing-european-biotechnology 2024-09-17T13:20:13+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-approval-total-knee-study-company-announcement-investegate 2024-09-17T13:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/ritedose-is-proud-to-partner-with-verona-pharma-to-deliver-first-in-class-copd-drug 2024-09-17T12:30:21+00:00 weekly 0.7 https://trial.medpath.com/news/ohio-state-s-novel-dhodh-inhibitor-enters-first-human-trials-news-medical 2024-09-17T12:27:37+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1s-can-potentially-cut-cirrhosis-related-complications-in-masld-study-biospace 2024-09-17T12:26:00+00:00 weekly 0.7 https://trial.medpath.com/news/leukemia-survivor-breast-cancer-caregiver-why-i-joined-md-anderson-s-boot-walk-to-end 2024-09-17T12:16:01+00:00 weekly 0.7 https://trial.medpath.com/news/endomimeticstm-awarded-2-8-million-phase-ii-sbir-grant-to-globenewswire 2024-09-17T12:07:33+00:00 weekly 0.7 https://trial.medpath.com/news/rosacea-in-patients-of-color-experts-call-for-better-recognition-and-diagnosis 2024-09-17T12:00:57+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-announces-infigratinib-is-the-first-ever-investigational-therapeutic-option-stock-titan 2024-09-17T11:47:12+00:00 weekly 0.7 https://trial.medpath.com/news/innovation-driving-cancer-s-solid-tumors-market-aemd-stock-news 2024-09-17T11:45:59+00:00 weekly 0.7 https://trial.medpath.com/news/rocket-pharmaceuticals-announces-completion-of-enrollment-in-phase-2-pivotal-trial-of-rp 2024-09-17T11:45:08+00:00 weekly 0.7 https://trial.medpath.com/news/transcode-therapeutics-announces-first-patients-treated-in-phase-1-clinical-trial-with 2024-09-17T11:44:29+00:00 weekly 0.7 https://trial.medpath.com/news/guard-therapeutics-phase-2-results-published-in-leading-scientific-journal-placera 2024-09-17T11:35:26+00:00 weekly 0.7 https://trial.medpath.com/news/poseida-therapeutics-p-bcma-allo1-receives-us-fda-rmat-designation-to-treat 2024-09-17T11:30:18+00:00 weekly 0.7 https://trial.medpath.com/news/beigene-receives-israeli-ministry-of-health-approval-for-tevimbra-r-for-the-treatment-of 2024-09-17T11:12:10+00:00 weekly 0.7 https://trial.medpath.com/news/cullinan-therapeutics-receives-approval-to-initiate-its-global-phase-1-clinical-trial-of-cln 2024-09-17T11:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/boston-scientific-receives-fda-approval-for-expanded-indication-of-ingevitytm-pacing 2024-09-17T11:01:01+00:00 weekly 0.7 https://trial.medpath.com/news/synbiotics-in-patients-at-risk-for-spontaneous-preterm-birth-protocol-for-a-multi-centre 2024-09-17T10:33:23+00:00 weekly 0.7 https://trial.medpath.com/news/ascletis-enters-the-obesity-drug-space-with-announcement-of-two-ongoing-u-s-phase-i 2024-09-17T10:26:17+00:00 weekly 0.7 https://trial.medpath.com/news/ferrer-advances-research-into-progressive-supranuclear-palsy-psp-with-the-inclusion-of 2024-09-17T09:57:08+00:00 weekly 0.7 https://trial.medpath.com/news/little-pre-and-postmarket-testing-for-most-recalled-cv-devices-tctmd-com 2024-09-17T09:35:05+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-phase-iii-natalee-trial-of-kisqali-shows-deepening-benefit-in-new-analysis 2024-09-17T09:29:25+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-imfinzi-and-imjudo-found-to-extend-survival-in-liver-cancer-trial 2024-09-17T09:17:43+00:00 weekly 0.7 https://trial.medpath.com/news/combo-treatment-doubles-survival-for-patients-with-advanced-kidney-cancer 2024-09-17T09:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/pipeline-watch-four-approvals-and-32-phase-iii-readouts-scrip-citeline 2024-09-17T08:38:45+00:00 weekly 0.7 https://trial.medpath.com/news/minervax-and-wacker-biotech-announce-manufacturing-collaboration-for-prophylactic 2024-09-17T07:31:49+00:00 weekly 0.7 https://trial.medpath.com/news/expert-highlights-critical-role-of-early-diagnosis-and-targeted-therapy-in-bpdcn-management 2024-09-17T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/karolinska-development-s-portfolio-company-anacardio-reports-progress-in-two-clinical 2024-09-17T06:39:33+00:00 weekly 0.7 https://trial.medpath.com/news/studies-show-immunotherapy-improves-long-term-survival-in-growing-number-of-cancers 2024-09-17T05:42:49+00:00 weekly 0.7 https://trial.medpath.com/news/mortality-and-functional-outcomes-18-months-after-hospitalization-for-covid-19-in-geriatric-patients 2024-09-17T05:36:39+00:00 weekly 0.7 https://trial.medpath.com/news/ai-powered-data-integration-revolutionizes-drug-diversion-detection-in-healthcare-systems 2024-09-17T05:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-09-17T04:51:08+00:00 weekly 0.7 https://trial.medpath.com/news/spinal-muscular-atrophy-clinical-trials-2024-updated-ema-openpr-com 2024-09-17T04:33:55+00:00 weekly 0.7 https://trial.medpath.com/news/lykos-could-see-five-year-delay-in-possible-fda-approval-of-mdma-inside-health-policy 2024-09-17T02:17:20+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-draft-guidance-on-conducting-multiregional-clinical-trials-in-oncology 2024-09-17T02:07:22+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-announces-updated-results-from-versatile-002-phase-2-clinical-trial 2024-09-17T02:07:19+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-fecal-microbiota-transplantation-vs-placebo-in-patients-receiving-urotoday 2024-09-17T01:35:45+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-perioperative-imfinzi-significantly-extends-survival-in-type-of-bladder-cancer 2024-09-17T01:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/pharmaust-seeks-european-orphan-drug-designation-for-mnd-als-drug-monepantel 2024-09-17T00:43:13+00:00 weekly 0.7 https://trial.medpath.com/news/drug-safety-experts-call-for-enhanced-diagnostic-accuracy-in-clinical-trials-to-protect-patient-safety 2024-09-17T00:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/ipf-drug-meets-primary-end-point-managed-healthcare-executive 2024-09-17T00:24:40+00:00 weekly 0.7 https://trial.medpath.com/news/launch-of-yselty-r-generic-name-linzagolix-for-uterine-fibroid-treatment-in-europe 2024-09-17T00:21:55+00:00 weekly 0.7 https://trial.medpath.com/news/5-year-analysis-of-phase-iii-himalaya-confirms-survival-benefit-of-stride-in 2024-09-16T22:22:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-manufacturing-line-for-rsv-therapy-becker-s-hospital-review 2024-09-16T21:58:48+00:00 weekly 0.7 https://trial.medpath.com/news/elderly-monkeys-aged-more-slowly-when-given-a-cheap-diabetes-drug-used-by-millions 2024-09-16T21:42:16+00:00 weekly 0.7 https://trial.medpath.com/news/darolutamide-in-combination-with-androgen-deprivation-therapy-in-patients-with-urotoday 2024-09-16T21:25:51+00:00 weekly 0.7 https://trial.medpath.com/news/qu-scientists-in-precision-medicine-breakthrough-gulf-times 2024-09-16T21:08:54+00:00 weekly 0.7 https://trial.medpath.com/news/pei-yu-chen-phd-aims-to-create-a-safer-and-more-effective-way-to-deliver-drugs 2024-09-16T21:07:48+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-trial-highlights-potential-of-inavolisib-for-pik3ca-mutated-cancers 2024-09-16T21:03:01+00:00 weekly 0.7 https://trial.medpath.com/news/poor-outcomes-after-tpoxx-mpox-treatment-mainly-seen-in-those-with-weak-immunity 2024-09-16T20:47:54+00:00 weekly 0.7 https://trial.medpath.com/news/biotronik-catheter-gets-fda-approval-daic 2024-09-16T20:44:43+00:00 weekly 0.7 https://trial.medpath.com/news/duke-physician-highlights-positive-ovarian-cancer-clinical-trial-results 2024-09-16T20:44:37+00:00 weekly 0.7 https://trial.medpath.com/news/amg-193-shows-preliminary-clinical-activity-in-mtap-deleted-solid-tumors-onclive 2024-09-16T20:28:10+00:00 weekly 0.7 https://trial.medpath.com/news/brain-metastases-of-her2-positive-breast-cancer-patients-effectively-treated-with-antibody 2024-09-16T20:23:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-apple-watch-sleep-apnea-detection-notification-appleinsider 2024-09-16T20:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-mm-ii-fast-track-designation-for-treatment-of-osteoarthritis-knee-pain 2024-09-16T20:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/fda-drafts-guidance-on-multiregional-clinical-trials-in-oncology-raps 2024-09-16T19:49:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lebrikizumab-for-treatment-of-atopic-dermatitis-pharmacy-times 2024-09-16T19:48:49+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-insights-epcoritamab-in-relapsed-refractory-follicular-lymphoma-onclive 2024-09-16T19:44:49+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-announce-clinical-trial-results-for-hard-to-treat-breast-and-bladder-cancers 2024-09-16T19:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-sny-win-fda-approval-for-a-broader-dupixent-label-yahoo-finance 2024-09-16T19:08:43+00:00 weekly 0.7 https://trial.medpath.com/news/newly-initiated-phase-2-breakthrough-trial-to-test-5-ht2c-receptor-agonist-bmb-101 2024-09-16T19:08:27+00:00 weekly 0.7 https://trial.medpath.com/news/keynote-522-findings-continue-to-shape-the-future-of-tnbc-care-targeted-oncology 2024-09-16T19:05:19+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-improves-outcomes-in-high-risk-bladder-cancer-nci 2024-09-16T18:44:32+00:00 weekly 0.7 https://trial.medpath.com/news/techcrunch-minute-fda-approval-sets-the-stage-for-apple-s-airpod-hearing-aids 2024-09-16T18:38:27+00:00 weekly 0.7 https://trial.medpath.com/news/apple-gets-fda-approval-for-smartwatch-sleep-apnea-detection-feature-investopedia 2024-09-16T18:29:11+00:00 weekly 0.7 https://trial.medpath.com/news/tremelimumab-plus-durvalumab-turns-heads-with-updated-five-year-data-in-uhcc 2024-09-16T18:27:31+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-and-novel-targeted-drug-appear-beneficial-in-women-with-early-stage 2024-09-16T18:27:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-apple-s-sleep-apnea-detection-feature-for-use-here-s-how-it-works-cnbc 2024-09-16T18:12:04+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ebglyss-for-moderate-to-severe-atopic-dermatitis-pharmaceutical-executive 2024-09-16T18:09:15+00:00 weekly 0.7 https://trial.medpath.com/news/new-eli-lilly-eczema-drug-brings-competition-and-dosing-edge-versus-sanofi-leo-pharma-meds 2024-09-16T17:56:47+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-scores-fda-approval-for-eczema-treatment-ebglyss-benzinga 2024-09-16T17:52:46+00:00 weekly 0.7 https://trial.medpath.com/news/recon-astrazeneca-releases-positive-results-on-imfinzi-for-bladder-cancer-raps 2024-09-16T17:26:56+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-biotronik-lead-catheter-for-left-bundle-branch-area-pacing 2024-09-16T17:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/medical-marijuana-users-see-short-term-gains-in-he-newswise 2024-09-16T17:06:34+00:00 weekly 0.7 https://trial.medpath.com/news/evaxion-reports-convincing-one-year-data-from-phase-2-trial-on-ai-designed-personalized 2024-09-16T17:02:55+00:00 weekly 0.7 https://trial.medpath.com/news/rewriting-the-health-care-script-in-africa-c-en-american-chemical-society 2024-09-16T16:48:05+00:00 weekly 0.7 https://trial.medpath.com/news/dr-nicolas-girard-on-luminosity-teliso-v-improves-pros-in-nsclc 2024-09-16T16:47:04+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-gains-fda-approval-for-expanded-use-in-adolescents-with-crswnp 2024-09-16T16:46:25+00:00 weekly 0.7 https://trial.medpath.com/news/leigh-s-lost-and-found-local-vet-office-takes-part-in-clinical-trial-to-extend-dogs-lives-ky3 2024-09-16T16:42:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-catheter-system-for-left-bundle-branch-area-pacing-healio 2024-09-16T16:35:11+00:00 weekly 0.7 https://trial.medpath.com/news/icmr-signs-agreements-for-first-in-human-clinical-trials-of-four-new-molecules 2024-09-16T16:35:08+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T16:33:01+00:00 weekly 0.7 https://trial.medpath.com/news/inspiremd-submits-carotid-stent-for-fda-premarket-approval-massdevice 2024-09-16T16:28:03+00:00 weekly 0.7 https://trial.medpath.com/news/apple-watch-s-sleep-apnea-detection-feature-gets-fda-approval-here-s-how-it-will-work 2024-09-16T16:27:30+00:00 weekly 0.7 https://trial.medpath.com/news/pipeline-moves-novo-nordisk-s-liraglutide-scores-in-phase-iii-paediatric-trial 2024-09-16T16:24:30+00:00 weekly 0.7 https://trial.medpath.com/news/apple-watch-sleep-apnea-detection-gets-fda-approval-healthleaders-media 2024-09-16T16:13:15+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-hold-on-zentalis-cancer-drug-trials-investing-com 2024-09-16T16:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ocrevus-zunovo-for-relapsing-primary-progressive-multiple-sclerosis 2024-09-16T16:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-seeks-approval-for-lung-fibrosis-drug-following-phase-iii-win-yahoo 2024-09-16T16:08:48+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-of-its-kind-cardiac-stent-for-babies-newswise 2024-09-16T16:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/50-years-of-the-cure-celebrating-pioneering-iu-research-and-the-cure-for-testicular-cancer 2024-09-16T16:07:02+00:00 weekly 0.7 https://trial.medpath.com/news/splash-177lu-pnt2002-achieves-phase-3-outcomes-for-mcrpc-urology-times 2024-09-16T16:04:04+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-after-surgery-helps-people-with-high-risk-bladder-cancer-live-cancer-free-longer 2024-09-16T15:56:31+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-nivolumab-or-nivolumab-plus-ipilimumab-in-early-stage-triple-negative-breast-cancer 2024-09-16T15:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/ten-year-data-from-checkmate-067-trial-shows-long-term-survival-benefits-of-opdivo 2024-09-16T15:46:39+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-plus-imjudo-shows-significant-five-year-survival-improvement-in-unresectable-liver-cancer 2024-09-16T15:46:39+00:00 weekly 0.7 https://trial.medpath.com/news/chemo-free-triplet-yields-68-response-rate-in-richter-transformation-medpage-today 2024-09-16T15:45:37+00:00 weekly 0.7 https://trial.medpath.com/news/new-eczema-drug-from-eli-lilly-receives-fda-approval-for-children-and-adults-usa-today 2024-09-16T15:42:45+00:00 weekly 0.7 https://trial.medpath.com/news/alliance-presents-final-results-from-phase-ii-eurekalert 2024-09-16T15:42:23+00:00 weekly 0.7 https://trial.medpath.com/news/guru-sonpavde-md-on-phase-3-ambassador-trial-data-in-urothelial-carcinoma 2024-09-16T15:40:56+00:00 weekly 0.7 https://trial.medpath.com/news/pooled-trust-i-and-trust-ii-data-affirm-taletrectinib-benefits-for-advanced-ros1-nsclc 2024-09-16T15:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-partial-clinical-hold-on-trials-evaluating-azenosertib-in-advanced-solid-tumors 2024-09-16T15:40:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-p-bcma-allo1-rmat-designation-in-r-r-multiple-myeloma 2024-09-16T15:35:05+00:00 weekly 0.7 https://trial.medpath.com/news/epitomee-medical-announces-fda-clearance-of-its-capsule-weight-management-device 2024-09-16T15:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-targets-expanded-use-approval-for-prostate-cancer-drug-reveals-encouraging 2024-09-16T15:21:07+00:00 weekly 0.7 https://trial.medpath.com/news/biotronik-earns-expanded-fda-nod-for-pacing-lead-delivery-catheter-system-massdevice 2024-09-16T15:19:54+00:00 weekly 0.7 https://trial.medpath.com/news/addressing-disparities-in-food-allergen-immunotherapy-trials-jama-network 2024-09-16T15:18:16+00:00 weekly 0.7 https://trial.medpath.com/news/first-group-of-healthy-volunteers-dosed-in-qrl-101-mad-study-als-news-today 2024-09-16T15:14:15+00:00 weekly 0.7 https://trial.medpath.com/news/epitomee-medical-announces-fda-clearance-of-its-capsule-weight-management-device 2024-09-16T15:13:03+00:00 weekly 0.7 https://trial.medpath.com/news/some-men-with-prostate-cancer-can-benefit-from-immunotherapy 2024-09-16T15:12:34+00:00 weekly 0.7 https://trial.medpath.com/news/apple-watch-sleep-apnea-detection-gets-fda-clearance-the-verge 2024-09-16T15:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/weekly-review-dupilumab-lebrikizumab-fda-approved-plus-much-more-contemporary-pediatrics 2024-09-16T15:11:59+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-could-curb-progression-of-diabetes-linked-liver-disease 2024-09-16T15:09:52+00:00 weekly 0.7 https://trial.medpath.com/news/three-apple-watches-get-fda-approval-for-sleep-apnea-detection-from-today-9to5mac 2024-09-16T15:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/perioperative-durvalumab-with-neoadjuvant-chemo-boosts-survival-in-cisplatin-eligible-mibc 2024-09-16T15:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lebrikizumab-for-patients-aged-12-and-older-with-moderate-to-severe 2024-09-16T15:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/ipsen-shelves-cabometyx-combo-in-prostate-cancer-after-phase-iii-miss 2024-09-16T15:00:26+00:00 weekly 0.7 https://trial.medpath.com/news/apac-roundup-cdsco-releases-draft-guidelines-on-good-clinical-practices-for-consultation-raps 2024-09-16T14:59:57+00:00 weekly 0.7 https://trial.medpath.com/news/leap-012-pembrolizumab-plus-lenvatinib-added-to-tace-improved-progression-free 2024-09-16T14:51:36+00:00 weekly 0.7 https://trial.medpath.com/news/positive-trial-demonstrates-safe-breastfeeding-during-endocrine-therapy-break-for-hr-breast-cancer-patients 2024-09-16T14:48:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-tecentriq-hybreza-cancer-therapy-advisor 2024-09-16T14:47:48+00:00 weekly 0.7 https://trial.medpath.com/news/ocrevus-zunovo-now-approved-in-us-to-treat-relapsing-ms-ppms 2024-09-16T14:44:02+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-shipping-beyfortus-r-in-us-to-help-protect-babies-against-rsv-disease 2024-09-16T14:43:07+00:00 weekly 0.7 https://trial.medpath.com/news/new-trial-to-test-potential-treatment-for-chronic-kidney-disease 2024-09-16T14:43:06+00:00 weekly 0.7 https://trial.medpath.com/news/velsera-technology-paves-the-way-for-advanced-cancer-diagnostics-with-fda-approval-of 2024-09-16T14:42:48+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-breast-cancer-drug-found-to-cut-disease-recurrence-investopedia 2024-09-16T14:33:42+00:00 weekly 0.7 https://trial.medpath.com/news/risk-for-second-primary-cancer-may-be-no-higher-with-car-t-cell-versus-standard-of-care 2024-09-16T14:32:07+00:00 weekly 0.7 https://trial.medpath.com/news/sec-form-424b5-filed-by-inmune-bio-inc-quantisnow 2024-09-16T14:26:45+00:00 weekly 0.7 https://trial.medpath.com/news/trishula-therapeutics-presents-positive-results-from-phase-1-trial-of-ttx-030-in-first-line-metastatic-pancreatic-cancer-patients 2024-09-16T14:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-and-adjuvant-pembrolizumab-extends-survival-in-early-stage-tnbc 2024-09-16T14:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-drug-treating-fatal-weight-loss-in-cancer-patients-found-effective-investopedia 2024-09-16T13:57:16+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-pfizer-s-cachexia-drug-provides-meaningful-weight-gain-clinical-trials-arena 2024-09-16T13:56:08+00:00 weekly 0.7 https://trial.medpath.com/news/apple-watch-sleep-apnea-detection-gets-fda-approval-techcrunch 2024-09-16T13:48:07+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-j-j-cues-up-phase-3-for-rybrevant-in-colorectal-cancer-pharmaphorum 2024-09-16T13:36:22+00:00 weekly 0.7 https://trial.medpath.com/news/apple-watch-s-sleep-apnea-notification-feature-granted-fda-approval-tom-s-guide 2024-09-16T13:34:37+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-pfizer-s-cachexia-drug-provides-meaningful-weight-gain-yahoo-finance 2024-09-16T13:31:27+00:00 weekly 0.7 https://trial.medpath.com/news/alliance-unveils-phase-iii-cabozantinib-trial-results-at-esmo-mirage-news 2024-09-16T13:30:47+00:00 weekly 0.7 https://trial.medpath.com/news/vera-therapeutics-to-host-in-person-r-d-day-in-new-york-to-discuss-potential-indication 2024-09-16T13:30:30+00:00 weekly 0.7 https://trial.medpath.com/news/biovie-secures-all-scientific-approvals-needed-to-receive-additional-12-6-million-of-grant 2024-09-16T13:30:30+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T13:29:56+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-announces-updated-data-from-versatile-002-phase-2-study-in-hnscc 2024-09-16T13:26:55+00:00 weekly 0.7 https://trial.medpath.com/news/cvkd-new-blood-thinner-ready-for-phase-3-initiating-coverage-of-cadrenal-therapeutics-inc 2024-09-16T13:24:34+00:00 weekly 0.7 https://trial.medpath.com/news/nimmune-biopharma-to-participate-in-ubs-virtual-biotechnology-private-company-symposium 2024-09-16T13:19:09+00:00 weekly 0.7 https://trial.medpath.com/news/apple-watch-s-sleep-apnea-detection-feature-receives-fda-approval-macrumors 2024-09-16T13:12:39+00:00 weekly 0.7 https://trial.medpath.com/news/vivtex-enters-new-research-agreement-with-equillium-to-develop-gi-targeted-formulations 2024-09-16T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/second-generation-of-i-spy-2-trial-design-is-driving-the-precise-in-precision-medicine 2024-09-16T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/t2-biosystems-receives-fda-clearance-to-market-the-t2candida-panel-for-pediatric-patients 2024-09-16T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-shipping-beyfortus-r-in-us-to-help-protect-babies-against-rsv-disease-new 2024-09-16T13:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/shuttle-pharma-expands-clinical-trial-site-enrollment-for-phase-2-of-ropidoxuridine-stock-titan 2024-09-16T13:01:22+00:00 weekly 0.7 https://trial.medpath.com/news/t2-biosystems-receives-fda-clearance-to-market-the-t2candida-panel-for-pediatric-patients 2024-09-16T13:01:19+00:00 weekly 0.7 https://trial.medpath.com/news/final-results-from-cabinet-phase-iii-trial-reinforce-efficacy-benefits-of-cabometyx-tradingview 2024-09-16T12:53:30+00:00 weekly 0.7 https://trial.medpath.com/news/final-results-from-cabinet-phase-iii-trial-reinforce-efficacy-benefits-of-cabometyx-r-in-ipsen 2024-09-16T12:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/don-t-count-out-cipher-pharma-research-capital-says-cantech-letter 2024-09-16T12:52:39+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-iteos-score-phase-ii-win-for-jemperli-tigit-combo-in-nsclc-biospace 2024-09-16T12:52:21+00:00 weekly 0.7 https://trial.medpath.com/news/final-results-from-cabinet-phase-iii-trial-reinforce-globenewswire 2024-09-16T12:50:51+00:00 weekly 0.7 https://trial.medpath.com/news/september-16-2024-researchers-examine-feasibility-of-enhanced-tsos-intervention-for 2024-09-16T12:50:17+00:00 weekly 0.7 https://trial.medpath.com/news/final-results-from-cabinet-phase-iii-trial-reinforce-efficacy-benefits-of-cabometyx-r-in 2024-09-16T12:49:05+00:00 weekly 0.7 https://trial.medpath.com/news/clene-granted-in-person-meeting-with-fda-senior-leadership-to-discuss-cnm-au8 2024-09-16T12:42:23+00:00 weekly 0.7 https://trial.medpath.com/news/china-grants-btd-to-blenrep-with-bordex-for-multiple-myeloma 2024-09-16T12:41:07+00:00 weekly 0.7 https://trial.medpath.com/news/velsera-technology-paves-the-way-for-advanced-cancer-diagnostics-with-fda-approval-of 2024-09-16T12:39:11+00:00 weekly 0.7 https://trial.medpath.com/news/mizuho-maintains-neutral-rating-on-apellis-stock-with-steady-price-target-investing-com 2024-09-16T12:37:27+00:00 weekly 0.7 https://trial.medpath.com/news/data-from-a-phase-1-trial-of-highfield-biopharmaceuticals-hf1k16-show-the-new-immuno 2024-09-16T12:36:58+00:00 weekly 0.7 https://trial.medpath.com/news/bio-path-holdings-announces-publication-in-biomedicines-biospace 2024-09-16T12:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/passage-bio-to-present-positive-interim-data-from-cohort-1-patients-with-ftd-grn-in-uplift 2024-09-16T12:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/gigapath-ai-model-shows-superior-accuracy-in-predicting-cancer-mutations-and-tumor-burden 2024-09-16T12:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-aims-for-single-dose-malaria-cure-with-a-novel-moa-long-acting-aryl-sf5-compound 2024-09-16T12:25:49+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-injectable-pd-l1-inhibitor-granted-fda-approval-for-multiple-cancer-types-pmlive 2024-09-16T12:21:28+00:00 weekly 0.7 https://trial.medpath.com/news/new-research-highlights-complexities-of-central-centrifugal-cicatricial-alopecia-in-diverse-populations 2024-09-16T12:21:09+00:00 weekly 0.7 https://trial.medpath.com/news/poseida-therapeutics-receives-regenerative-medicine-advanced-therapy-rmat-stock-titan 2024-09-16T12:20:17+00:00 weekly 0.7 https://trial.medpath.com/news/infex-therapeutics-first-ncfb-patient-dosed-in-resp-x-phase-iia-study-research-tree 2024-09-16T12:19:45+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotechnology-corporation-announces-updated-results-from-versatile-002-phase 2024-09-16T12:15:57+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-aranote-trial-shows-nubeqa-r-darolutamide-significantly-reduced-risk-of 2024-09-16T12:10:19+00:00 weekly 0.7 https://trial.medpath.com/news/aethlon-medical-announces-activation-of-royal-adelaide-hospital-to-begin-patient-markets-data 2024-09-16T12:09:33+00:00 weekly 0.7 https://trial.medpath.com/news/poseida-therapeutics-receives-regenerative-medicine-advanced-therapy-rmat-placera 2024-09-16T12:05:24+00:00 weekly 0.7 https://trial.medpath.com/news/inspiremd-announces-submission-of-premarket-approval-application-to-fda-seeking-u-s 2024-09-16T11:59:40+00:00 weekly 0.7 https://trial.medpath.com/news/pivotal-approach-trial-of-transcontm-cnp-navepegritide-achieved-primary-markets-insider 2024-09-16T11:59:40+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-niagara-backs-imfinzi-in-bladder-cancer-but-will-fda-pharmaphorum 2024-09-16T11:58:24+00:00 weekly 0.7 https://trial.medpath.com/news/inspiremd-seeks-fda-approval-for-carotid-stent-system-investing-com 2024-09-16T11:49:51+00:00 weekly 0.7 https://trial.medpath.com/news/evaxion-reports-promising-phase-2-trial-results-for-cancer-vaccine-investing-com 2024-09-16T11:49:49+00:00 weekly 0.7 https://trial.medpath.com/news/medexus-provides-update-on-treosulfan-nda-review-process-and-extended-pdufa-goal-date 2024-09-16T11:48:34+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-announces-fda-approval-for-ebglyss-in-moderate-to-severe-atopic-dermatitis 2024-09-16T11:43:28+00:00 weekly 0.7 https://trial.medpath.com/news/blenrep-belantamab-mafodotin-in-combination-receives-breakthrough-therapy-marketscreener 2024-09-16T11:37:45+00:00 weekly 0.7 https://trial.medpath.com/news/biontech-upgraded-by-jp-morgan-with-a-new-price-target-quantisnow 2024-09-16T11:36:47+00:00 weekly 0.7 https://trial.medpath.com/news/zentalis-pharmaceuticals-announces-fda-has-lifted-partial-clinical-hold-on-azenosertib-studies 2024-09-16T11:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/japan-s-mhlw-approves-csl-arcturus-updated-sa-mrna-covid-19-vaccine-for 2024-09-16T11:29:39+00:00 weekly 0.7 https://trial.medpath.com/news/phytohealth-corporation-announced-a-new-clinical-study-results-published-at-2024-esmo-congress 2024-09-16T11:23:12+00:00 weekly 0.7 https://trial.medpath.com/news/acrivon-therapeutics-promising-trial-results-and-fda-clearance-tipranks-com 2024-09-16T11:20:36+00:00 weekly 0.7 https://trial.medpath.com/news/pivotal-approach-trial-of-transcontm-cnp-navepegritide-achieved-primary-stock-titan 2024-09-16T11:19:08+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-announces-updated-results-from-versatile-002-phase-2-clinical-trial 2024-09-16T11:19:03+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotechnology-announces-updates-data-from-versatile-002-trial-tipranks-com 2024-09-16T11:15:23+00:00 weekly 0.7 https://trial.medpath.com/news/passage-bio-to-present-positive-interim-data-from-cohort-1-globenewswire 2024-09-16T11:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-is-a-game-changer-in-heart-valve-technology-health-tech-world 2024-09-16T11:07:33+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-announces-updated-analysis-from-phase-iii-natalee-trial-tipranks-com 2024-09-16T11:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-r-durvalumab-plus-imjudo-r-tremelimumab-actl-demonstrated-unprecedented 2024-09-16T11:03:31+00:00 weekly 0.7 https://trial.medpath.com/news/strides-pharma-gets-fda-nod-for-generic-antidepressant-fluoxetine-60-mg-tablet 2024-09-16T11:02:32+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-announces-updated-results-from-versatile-002-globenewswire 2024-09-16T11:02:07+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T11:01:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-roche-s-ocrevus-zunovo-with-halozyme-enhanze-delivery-tech 2024-09-16T10:55:21+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T10:49:54+00:00 weekly 0.7 https://trial.medpath.com/news/epitomee-surges-200-in-two-days-on-fda-approval-for-weight-loss-pill-ctech 2024-09-16T10:49:14+00:00 weekly 0.7 https://trial.medpath.com/news/antennova-releases-latest-data-of-cd73-inhibitor-atn-037-including-a-dcr-of-89-5-in-a 2024-09-16T10:41:23+00:00 weekly 0.7 https://trial.medpath.com/news/promising-anti-tumor-activity-and-safety-of-ivonescimab-in-combination-therapies-in-crc 2024-09-16T10:41:23+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-regeneron-s-melanoma-combo-therapy-benefit-continues-beyond-two-years 2024-09-16T10:31:15+00:00 weekly 0.7 https://trial.medpath.com/news/pd-1-checkpoint-inhibitor-shows-promise-for-anal-cancer 2024-09-16T10:29:17+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-boosts-weight-loss-pill-co-epitomee-globes-english-glvbs 2024-09-16T10:28:36+00:00 weekly 0.7 https://trial.medpath.com/news/niagara-durvalumab-plus-chemo-improves-efs-and-os-in-cisplatin-eligible-mibc 2024-09-16T10:19:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-otc-hearing-aid-software-pharmaceutical-executive 2024-09-16T10:18:57+00:00 weekly 0.7 https://trial.medpath.com/news/in-vivo-car-t-cells-move-into-clinical-trials-nature 2024-09-16T10:18:13+00:00 weekly 0.7 https://trial.medpath.com/news/patientseek-identifies-a-genetic-signature-that-separates-a4b7-integrin-therapy-responder 2024-09-16T10:09:23+00:00 weekly 0.7 https://trial.medpath.com/news/certa-therapeutics-announces-international-non-proprietary-name-for-its-first-in-class 2024-09-16T10:09:23+00:00 weekly 0.7 https://trial.medpath.com/news/this-drug-shows-promise-in-extending-bladder-cancer-patients-lives-newsbytes 2024-09-16T09:59:08+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-receives-fda-approval-as-first-crswnp-treatment-pharmaceutical-technology 2024-09-16T09:58:59+00:00 weekly 0.7 https://trial.medpath.com/news/medsir-presents-new-studies-at-esmo-that-advance-treatment-of-patients-with-poor 2024-09-16T09:50:05+00:00 weekly 0.7 https://trial.medpath.com/news/deep-behavioural-representation-learning-reveals-risk-profiles-for-malignant-ventricular-arrhythmias 2024-09-16T09:38:17+00:00 weekly 0.7 https://trial.medpath.com/news/elicio-therapeutics-announces-three-upcoming-presentations-focused-on-its-lymph-node 2024-09-16T09:37:09+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-presents-positive-data-from-phase-2-study-of-ponsegromab-in-patients-with-cancer-cachexia 2024-09-16T09:37:08+00:00 weekly 0.7 https://trial.medpath.com/news/io-biotech-announces-positive-results-from-phase-2-trial-of-io102-io103-in-the-first-line 2024-09-16T09:37:07+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ocrevus-zunovotm-as-the-first-and-only-twice-a-year-10-minute-biospace 2024-09-16T09:37:06+00:00 weekly 0.7 https://trial.medpath.com/news/daiichi-sankyo-posts-positive-ds-9606-clinical-trial-results-in-solid-tumours 2024-09-16T09:27:54+00:00 weekly 0.7 https://trial.medpath.com/news/natera-announces-three-new-signatera-publications-includes-groundbreaking-overall 2024-09-16T09:26:06+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-secures-fda-approval-for-ebglyss-to-treat-atopic-dermatitis 2024-09-16T09:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/daiichi-sankyo-posts-positive-ds-9606-clinical-trial-results-in-solid-tumours-yahoo-finance 2024-09-16T09:18:57+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-drugs-extend-survival-for-patients-with-advanced-melanomas 2024-09-16T09:09:09+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-kisqali-r-shows-deepening-benefit-in-new-analysis-reducing-the-risk-of-recurrence 2024-09-16T08:49:52+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-late-breaking-data-phase-iii-aranote-trial-shows-nubeqa-r-darolutamide 2024-09-16T08:49:10+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-late-breaking-data-phase-iii-aranote-trial-shows-nubeqa-r-darolutamide 2024-09-16T08:44:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-tremfya-r-for-ulcerative-colitis-treatment-promising-new-hope-for-patients 2024-09-16T08:32:40+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-kisqali-r-shows-deepening-benefit-in-new-analysis-globenewswire 2024-09-16T08:19:17+00:00 weekly 0.7 https://trial.medpath.com/news/gv20-therapeutics-reports-first-clinical-data-for-ai-designed-checkpoint-inhibitor-gv20-0251-in-advanced-solid-tumors 2024-09-16T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/diffuse-large-b-cell-lymphoma-is-curable-how-new-drug-polatuzumab-is-working-wonders 2024-09-16T07:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/feasibility-and-safety-of-pd-1-blockades-among-elderly-patients-with-p-dove-medical-press 2024-09-16T07:41:28+00:00 weekly 0.7 https://trial.medpath.com/news/fda-finalizes-guidance-on-dose-optimization-for-oncology-therapies-clinical-leader 2024-09-16T07:41:13+00:00 weekly 0.7 https://trial.medpath.com/news/roche-ocrevus-zunovo-approved-by-the-fda-marketscreener 2024-09-16T07:37:06+00:00 weekly 0.7 https://trial.medpath.com/news/lilly-s-ebglyss-gains-approval-for-patients-12-years-and-older 2024-09-16T07:31:01+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-trop2-directed-adcs-show-promise-in-recurrent-gynecological-cancers 2024-09-16T07:21:40+00:00 weekly 0.7 https://trial.medpath.com/news/alphamab-oncology-presented-the-latest-clinical-data-from-two-studies-on-anti-her2 2024-09-16T07:10:48+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-tigit-race-tightens-with-first-look-at-gsk-iteos-s-tigit-in-nsclc 2024-09-16T07:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/new-survey-reveals-12-of-americans-suffer-from-chronic-insomnia-as-sleep-health-concerns-rise 2024-09-16T07:06:07+00:00 weekly 0.7 https://trial.medpath.com/news/india-formalises-industry-partnerships-for-phase-one-clinical-trials-healthcare-asia 2024-09-16T06:59:04+00:00 weekly 0.7 https://trial.medpath.com/news/bavarian-nordic-s-mpox-vaccine-approved-by-who-medwatch 2024-09-16T06:56:04+00:00 weekly 0.7 https://trial.medpath.com/news/exact-sciences-colon-cancer-blood-test-shows-initial-promise-stat-news 2024-09-16T06:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-pembrolizumab-plus-chemotherapy-followed-by-adjuvant-pharmacy-times 2024-09-16T06:43:32+00:00 weekly 0.7 https://trial.medpath.com/news/torl-biotherapeutics-presents-updated-phase-1-results-of-novel-claudin-6-targeted-biospace 2024-09-16T06:41:24+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-incyte-s-pd-1-treads-new-ground-in-anal-cancer-pharmaphorum 2024-09-16T06:37:23+00:00 weekly 0.7 https://trial.medpath.com/news/erteilung-des-status-eines-therapiedurchbruchs-fur-sanbexin-sublingualtabletten-durch-die 2024-09-16T06:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-plus-imjudo-demonstrated-unprecedented-overall-survival-in-advanced-liver-cancer 2024-09-16T06:34:05+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-plus-imjudo-demonstrated-unprecedented-overall-survival-in-advanced-liver-cancer 2024-09-16T06:32:57+00:00 weekly 0.7 https://trial.medpath.com/news/l-agence-americaine-des-produits-alimentaires-et-medicamenteux-fda-accorde-pr-newswire 2024-09-16T06:26:51+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-ocrevus-zunovo-gets-fda-approval-to-treat-relapsing-and-progressive 2024-09-16T06:20:39+00:00 weekly 0.7 https://trial.medpath.com/news/investigational-rinatabart-sesutecan-rina-s-shows-promising-anti-tumor-activity-as-biospace 2024-09-16T06:15:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-biosimilar-landscape-growing-market-share-and-policy-changes-shape-future-access 2024-09-16T06:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/keynote-006-study-of-pembrolizumab-shows-continued-survival-benefits-in-advanced-melanoma 2024-09-16T06:07:55+00:00 weekly 0.7 https://trial.medpath.com/news/bicycle-therapeutics-presents-updated-clinical-results-across-oncology-pipeline-at-esmo 2024-09-16T05:57:15+00:00 weekly 0.7 https://trial.medpath.com/news/alphamab-oncology-presented-the-latest-clinical-data-from-two-studies-on-anti-her2 2024-09-16T05:32:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ocrevus-zunovotm-as-the-first-and-only-twice-a-year-10-minute 2024-09-16T05:17:01+00:00 weekly 0.7 https://trial.medpath.com/news/sutro-biopharma-announces-updated-data-from-phase-1b-study-of-luvelta-in-combination 2024-09-16T05:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/rybrevant-r-amivantamab-plus-chemotherapy-shows-positive-overall-survival-trend 2024-09-16T05:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-approves-eli-lilly-s-drug-for-eczema-express-pharma 2024-09-16T05:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/rp1-nivolumab-combo-shows-durable-responses-favorable-safety-in-melanoma 2024-09-16T05:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/association-between-intensive-blood-pressure-lowering-and-stroke-free-survival-among 2024-09-16T05:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-2024-2025-formula-covid-19-vaccine-available-at-major-pharmacies-across-the-u-s 2024-09-16T04:58:52+00:00 weekly 0.7 https://trial.medpath.com/news/early-data-shows-mrna-4359-may-benefit-patients-with-advanced-solid-cancers 2024-09-16T04:38:47+00:00 weekly 0.7 https://trial.medpath.com/news/kura-oncology-inc-latest-stock-news-market-updates 2024-09-16T04:29:57+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-roche-s-tecentriq-hybreza-the-first-and-only-subcutaneous-anti-pd-l-cancer 2024-09-16T04:17:24+00:00 weekly 0.7 https://trial.medpath.com/news/5-late-stage-mrna-vaccines-to-watch-biospace 2024-09-16T04:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-action-alert-bms-merck-sanofi-regeneron-and-more-biospace 2024-09-16T04:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-action-alert-bms-merck-sanofi-regeneron-and-more-biospace 2024-09-16T04:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/dimerix-enters-key-collaboration-to-further-boost-action3-trial-recruitment-in-uk 2024-09-16T03:05:41+00:00 weekly 0.7 https://trial.medpath.com/news/remarkable-clinical-trial-results-shared-internationally-ansto 2024-09-16T02:16:46+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-breakthrough-shared-globally-mirage-news 2024-09-16T02:13:09+00:00 weekly 0.7 https://trial.medpath.com/news/booker-schmitt-paul-king-braun-whitehouse-kennedy-lujan-blumenthal-introduce-the 2024-09-16T01:21:29+00:00 weekly 0.7 https://trial.medpath.com/news/t-dxd-maintains-qol-delays-pain-deterioration-in-hr-her2-low-ultralow-mbc 2024-09-16T01:12:50+00:00 weekly 0.7 https://trial.medpath.com/news/digital-support-app-launches-in-uk-to-address-rising-youth-cancer-cases 2024-09-16T01:07:18+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-anlotinib-and-penpulimab-gather-attention-in-hcc-with-apollo-results 2024-09-16T00:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-updates-in-penile-cancer-urotoday 2024-09-16T00:40:57+00:00 weekly 0.7 https://trial.medpath.com/news/who-approves-mpox-vaccine-for-babies-without-clinical-trials-the-conservative-woman 2024-09-16T00:38:37+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-dll-3-targeted-therapy-for-neuroendocrine-prostate-cancer-urotoday 2024-09-16T00:00:45+00:00 weekly 0.7 https://trial.medpath.com/news/ctdna-based-molecular-residual-disease-and-survival-in 2024-09-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-challenges-abbvie-s-serena-williams-ubrelvy-ad-for-misleading-migraine-claims 2024-09-15T23:49:42+00:00 weekly 0.7 https://trial.medpath.com/news/10-year-data-from-checkmate-067-confirms-survival-advantage-of-nivolumab-in-advanced 2024-09-15T23:44:26+00:00 weekly 0.7 https://trial.medpath.com/news/sintilimab-combined-with-anlotinib-and-chemotherapy-as-second-line-or-later-therapy-in-nature 2024-09-15T23:30:31+00:00 weekly 0.7 https://trial.medpath.com/news/radium-223-enhances-outcomes-with-enzalutamide-in-metastatic-castration-resistant 2024-09-15T23:00:21+00:00 weekly 0.7 https://trial.medpath.com/news/fecal-microbiota-transplant-boosts-immunotherapy-in-metastatic-renal-cell-carcinoma-in 2024-09-15T22:11:12+00:00 weekly 0.7 https://trial.medpath.com/news/azn-imfinzi-regimen-reduces-death-risk-by-25-in-late-stage-muscle-invasive 2024-09-15T22:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-r-dupilumab-approved-in-the-u-s-as-first-and-only-treatment-for-adolescents 2024-09-15T21:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lilly-s-ebglysstm-lebrikizumab-lbkz-for-adults-and-children-12-years-and 2024-09-15T21:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/torl-1-23-generates-responses-in-heavily-pretreated-cldn6-positive-solid-tumors 2024-09-15T21:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/liberty-cupid-study-c-confirms-benefit-of-dupilumab-in-biologic-naive-csu-hcplive 2024-09-15T21:07:01+00:00 weekly 0.7 https://trial.medpath.com/news/news-from-esmo-an-astrazeneca-win-in-bladder-cancer-and-more 2024-09-15T21:02:04+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-expands-beyond-cancer-new-frontiers-in-autoimmune-disease-treatment 2024-09-15T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ich-updates-guidelines-ngs-becomes-new-standard-for-viral-safety-testing-in-biotech-manufacturing 2024-09-15T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/systems-thinking-approach-could-revolutionize-clinical-trial-success-rates 2024-09-15T21:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/radionuclide-containing-combo-slows-metastatic-prostate-cancer-improves-survival 2024-09-15T20:25:14+00:00 weekly 0.7 https://trial.medpath.com/news/cyramza-plus-lonsurf-did-not-improve-survival-in-metastatic-colorectal-cancer 2024-09-15T20:20:36+00:00 weekly 0.7 https://trial.medpath.com/news/new-covid-vaccines-may-be-coming-to-australia-here-s-what-to-know-about-the-jn-1-shots 2024-09-15T20:14:39+00:00 weekly 0.7 https://trial.medpath.com/news/postsurgical-pembrolizumab-chemotherapy-misses-dfs-goal-in-endometrial-cancer 2024-09-15T20:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/advances-in-the-treatment-of-resectable-nsclc-key-insights-from-checkmate-77t 2024-09-15T20:12:02+00:00 weekly 0.7 https://trial.medpath.com/news/chemotherapy-de-escalation-associated-with-excellent-hr-her2-breast-cancer-survival 2024-09-15T19:35:38+00:00 weekly 0.7 https://trial.medpath.com/news/splash-trial-highlights-radiopharmaceutical-lutetium-177-s-role-in-advanced-prostate 2024-09-15T19:32:48+00:00 weekly 0.7 https://trial.medpath.com/news/no-smoking-startup-s-tiny-answer-to-safer-medical-cannabis-nocamels 2024-09-15T19:22:24+00:00 weekly 0.7 https://trial.medpath.com/news/lantheus-presents-results-from-the-primary-analysis-of-phase-3-pivotal-splash-trial-in 2024-09-15T19:13:53+00:00 weekly 0.7 https://trial.medpath.com/news/macrogenics-announces-updated-efficacy-safety-data-from-tamarack-phase-2-study 2024-09-15T19:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/akeso-published-first-ever-efficacy-data-for-pd-1-vegf-bispecific-antibody-ivonescimab 2024-09-15T19:10:53+00:00 weekly 0.7 https://trial.medpath.com/news/recent-health-headlines-fda-approvals-walgreens-settlement-and-more-devdiscourse 2024-09-15T19:03:36+00:00 weekly 0.7 https://trial.medpath.com/news/retifanlimab-plus-carboplatin-and-paclitaxel-improve-pfs-in-recurrent-metastatic-anal-cancer 2024-09-15T19:02:29+00:00 weekly 0.7 https://trial.medpath.com/news/apple-s-airpods-pro-2-revolutionize-hearing-aid-tech-with-fda-approval 2024-09-15T19:02:03+00:00 weekly 0.7 https://trial.medpath.com/news/atezolizumab-after-vemurafenib-and-cobimetinib-shows-trend-toward-better-os-in-melanoma 2024-09-15T18:59:33+00:00 weekly 0.7 https://trial.medpath.com/news/checkmate-77t-highlights-efs-benefit-in-perioperative-nivolumab-in-resectable-nsclc 2024-09-15T18:49:39+00:00 weekly 0.7 https://trial.medpath.com/news/icmr-formalises-moas-with-multiple-sponsors-under-phase-one-clinical-trials-network 2024-09-15T18:31:50+00:00 weekly 0.7 https://trial.medpath.com/news/early-switch-therapy-to-atezolizumab-after-vemurafenib-cobimetinib-run-in-improves-os 2024-09-15T18:31:12+00:00 weekly 0.7 https://trial.medpath.com/news/extended-follow-up-shows-dfs-benefit-for-pembrolizumab-in-miuc-urology-times 2024-09-15T17:58:48+00:00 weekly 0.7 https://trial.medpath.com/news/radiation-therapy-for-women-with-breast-cancer-will-now-last-for-no-more-than-three-weeks 2024-09-15T17:54:34+00:00 weekly 0.7 https://trial.medpath.com/news/missed-out-on-viking-therapeutics-buy-this-weight-loss-biotech-stock-right-now 2024-09-15T17:42:35+00:00 weekly 0.7 https://trial.medpath.com/news/incremental-effectiveness-costs-may-improve-using-biomarker-guided-selection 2024-09-15T17:31:45+00:00 weekly 0.7 https://trial.medpath.com/news/os-increase-observed-in-neoadjuvant-pembrolizumab-combo-plus-adjuvant-therapy-in-early-tnbc 2024-09-15T17:29:33+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-combo-shows-dfs-benefit-in-dmmr-endometrial-cancer-subgroup 2024-09-15T17:29:33+00:00 weekly 0.7 https://trial.medpath.com/news/queen-mary-university-of-london-researchers-announce-ground-breaking-clinical-trial 2024-09-15T17:16:22+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-pembrolizumab-chemo-adjuvant-pembrolizumab-boosts-os-in-early-tnbc 2024-09-15T17:12:08+00:00 weekly 0.7 https://trial.medpath.com/news/enhanced-progression-free-survival-with-retifanlimab-carboplatin-and-paclitaxel-in 2024-09-15T17:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approvals-fraud-settlements-and-global-health-initiatives-latest-health-news 2024-09-15T16:57:12+00:00 weekly 0.7 https://trial.medpath.com/news/doh-6-warns-public-on-unauthorized-mpox-vaccines-daily-guardian 2024-09-15T16:55:56+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-reveal-breakthrough-in-hard-to-treat-cancers-mirage-news 2024-09-15T16:49:22+00:00 weekly 0.7 https://trial.medpath.com/news/queen-mary-university-of-london-researchers-announce-ground-breaking-trial-results-for 2024-09-15T16:48:00+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-keynote-006-data-support-pembrolizumab-as-soc-in-advanced-melanoma 2024-09-15T16:35:03+00:00 weekly 0.7 https://trial.medpath.com/news/olaparib-cediranib-misses-survival-end-points-in-relapsed-ovarian-cancer-trial-onclive 2024-09-15T16:22:34+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-tar-200-phase-2b-sunrise-1-study-shows-84-complete-response-in-high-risk 2024-09-15T15:47:33+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-enhertu-to-eclipse-soc-for-her2-breast-cancer-with-brain-metastases 2024-09-15T15:23:01+00:00 weekly 0.7 https://trial.medpath.com/news/medilink-presents-yl201-b7h3-adc-at-esmo-2024-with-over-6-months-pfs-in-sclc 2024-09-15T15:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-immunotherapy-superior-to-targeted-therapy-in-stage-iii-melanoma 2024-09-15T15:10:18+00:00 weekly 0.7 https://trial.medpath.com/news/from-patient-to-entrepreneur-edmond-woman-creates-medical-device-kokh 2024-09-15T14:52:03+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-gsk-iteos-bring-some-optimism-back-to-tigit-pharmaphorum 2024-09-15T14:46:55+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-r-durvalumab-perioperative-regimen-reduced-the-risk-of-recurrence-by-32-and 2024-09-15T14:46:26+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-r-durvalumab-perioperative-regimen-reduced-the-risk-of-recurrence-by-32-and 2024-09-15T14:44:41+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-imfinzi-increases-survival-rates-in-bladder-cancer-stat-news 2024-09-15T14:43:01+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-tecentriq-avastin-s-prospects-as-the-first-hcc-adjuvant-therapy-fade 2024-09-15T14:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-presents-positive-data-from-phase-2-study-of-ponsegromab-in-patients-with-cancer-cachexia 2024-09-15T14:34:34+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-imfinzi-increases-survival-rates-in-bladder-cancer-stat-news 2024-09-15T14:31:46+00:00 weekly 0.7 https://trial.medpath.com/news/roswell-park-designed-treatment-regimen-doubles-progression-free-survival-in 2024-09-15T14:25:59+00:00 weekly 0.7 https://trial.medpath.com/news/prince-trial-highlights-early-detection-of-prostate-cancer-progression-with-psma-pet-ct 2024-09-15T14:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/disitamab-vedotin-promising-her2-targeted-therapy-for-urothelial-cancer-matthew-galsky 2024-09-15T14:14:46+00:00 weekly 0.7 https://trial.medpath.com/news/first-cancer-medicine-decision-following-pharmac-funding-boost-scoop-news 2024-09-15T14:10:40+00:00 weekly 0.7 https://trial.medpath.com/news/3d-systems-smith-nephew-announce-fda-clearance-for-total-ankle-replacement-solution 2024-09-15T14:06:58+00:00 weekly 0.7 https://trial.medpath.com/news/rybrevant-r-amivantamab-vmjw-plus-chemotherapy-show-49-percent-overall-response 2024-09-15T14:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/weekend-icymi-september-9-to-september-13-drug-topics 2024-09-15T14:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/advances-in-the-treatment-of-resectable-nsclc-key-insights-from-checkmate-77t 2024-09-15T13:59:55+00:00 weekly 0.7 https://trial.medpath.com/news/dr-angeles-alvarez-secord-on-exciting-responses-with-mirvetuximab-soravtansine-in 2024-09-15T13:55:52+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-presents-primary-analysis-data-from-ignyte-globenewswire 2024-09-15T13:49:27+00:00 weekly 0.7 https://trial.medpath.com/news/high-dose-vitamin-d3-does-not-provide-benefit-for-metastatic-colorectal-cancer 2024-09-15T13:49:21+00:00 weekly 0.7 https://trial.medpath.com/news/ambassador-trial-extended-follow-up-on-adjuvant-pembrolizumab-in-bladder-cancer 2024-09-15T13:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/scorpion-therapeutics-presents-initial-clinical-data-from-its-phase-1-2-trial-of-stx-478-kxra 2024-09-15T13:32:38+00:00 weekly 0.7 https://trial.medpath.com/news/the-dav132-colon-targeted-adsorbent-does-not-interfere-with-plasma-concentrations-of-nature 2024-09-15T13:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/who-prequalifies-a-mpox-vaccine-clearing-path-to-access-contagion-live 2024-09-15T13:28:37+00:00 weekly 0.7 https://trial.medpath.com/news/macrogenics-announces-updated-efficacy-safety-data-from-tamarack-phase-2-study-of-vobra 2024-09-15T13:24:30+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-presents-landmark-10-year-follow-up-data-from-checkmate-morningstar 2024-09-15T13:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/oncternal-therapeutics-axes-b-cell-lymphoma-trial-for-car-t-therapy-onct-808 2024-09-15T13:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/apple-gets-fda-approval-for-airpods-pro-2-hearing-aid-feature-here-is-how-it-can-help-people 2024-09-15T13:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-metastatic-melanoma-survival-dramatically-improves-on-immunotherapy-newsroom 2024-09-15T13:01:07+00:00 weekly 0.7 https://trial.medpath.com/news/investigational-rinatabart-sesutecan-rina-s-shows-promising-anti-tumor-activity-stock-titan 2024-09-15T12:59:29+00:00 weekly 0.7 https://trial.medpath.com/news/lantheus-presents-results-from-the-primary-analysis-of-phase-3-pivotal-splash-trial-in 2024-09-15T12:57:01+00:00 weekly 0.7 https://trial.medpath.com/news/investigational-rinatabart-sesutecan-rina-s-shows-promising-anti-tumor-yahoo-finance 2024-09-15T12:56:57+00:00 weekly 0.7 https://trial.medpath.com/news/lantheus-presents-results-from-the-primary-analysis-of-phase-3-pivotal-splash-trial-in 2024-09-15T12:56:05+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-metastatic-melanoma-survival-dramatically-improves-on-immunotherapy 2024-09-15T12:52:20+00:00 weekly 0.7 https://trial.medpath.com/news/ipsen-provides-update-on-contact-02-phase-iii-trial-in-metastatic-castration-resistant 2024-09-15T12:52:13+00:00 weekly 0.7 https://trial.medpath.com/news/ten-year-data-for-merck-s-keytruda-r-pembrolizumab-demonstrates-sustained-overall 2024-09-15T12:50:32+00:00 weekly 0.7 https://trial.medpath.com/news/ds-9606-shows-promising-preliminary-clinical-activity-in-patients-with-advanced-solid-tumors 2024-09-15T12:50:12+00:00 weekly 0.7 https://trial.medpath.com/news/new-data-from-tar-200-phase-2b-sunrise-1-study-show-84-globenewswire 2024-09-15T12:39:20+00:00 weekly 0.7 https://trial.medpath.com/news/new-data-from-tar-200-phase-2b-sunrise-1-study-show-84-percent-complete-response 2024-09-15T12:30:54+00:00 weekly 0.7 https://trial.medpath.com/news/lenvatinib-pembrolizumab-and-tace-demonstrate-significant-progression-free-survival 2024-09-15T11:08:49+00:00 weekly 0.7 https://trial.medpath.com/news/targeted-pulse-quiz-september-15 2024-09-15T11:04:17+00:00 weekly 0.7 https://trial.medpath.com/news/khcc-achieves-breakthrough-in-cancer-treatment-using-modified-t-lymphocytes 2024-09-15T10:31:48+00:00 weekly 0.7 https://trial.medpath.com/news/retina-society-2024-advances-in-amd-therapy-highlight-different-mechanisms-of-action-with 2024-09-15T10:17:30+00:00 weekly 0.7 https://trial.medpath.com/news/precede-biosciences-presents-new-data-at-esmo-2024-globenewswire 2024-09-15T10:07:14+00:00 weekly 0.7 https://trial.medpath.com/news/no-survival-gain-with-preoperative-crt-plus-perioperative-chemo-for-gastric-cancer 2024-09-15T09:59:47+00:00 weekly 0.7 https://trial.medpath.com/news/mayo-clinic-pharmacist-advocates-for-evidence-based-cannabis-discussions-in-cancer-care 2024-09-15T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-nivolumab-and-relatlimab-in-locally-advanced-mmr-deficient-colon-cancer 2024-09-15T07:45:33+00:00 weekly 0.7 https://trial.medpath.com/news/23andme-therapeutics-announces-phase-2-results-for-two-additional-cancer-cohorts-and 2024-09-15T07:25:18+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-chiefs-to-roll-out-new-drugs-for-lethal-lung-disease-that-took-life-of-star-trek-actor 2024-09-15T05:48:55+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-quality-gap-in-online-psoriasis-treatment-information-sources 2024-09-15T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/retina-society-2024-first-time-phase-2-clinical-trial-results-for-onl-1204-for 2024-09-15T04:10:08+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-as-scientists-develop-cancer-killing-treatment-that-preserves-healthy-body-cells 2024-09-15T01:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/novel-agents-and-promising-combinations-in-urothelial-and-renal-cell-carcinoma-urotoday 2024-09-15T00:51:27+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-shows-promise-for-maralixibat-in-treating-algs-related-cholestatic-pruritus 2024-09-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-dr-jonasch-on-implications-of-positive-hif-2a-inhibitor-data-in-ccrcc 2024-09-14T23:10:34+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-study-shows-comparable-outcomes-between-ct-p13-remicade-in-ra 2024-09-14T23:03:21+00:00 weekly 0.7 https://trial.medpath.com/news/gan-lee-pharmaceuticals-presented-two-positive-clinical-results-of-once-weekly-insulin 2024-09-14T23:00:58+00:00 weekly 0.7 https://trial.medpath.com/news/ipilimumab-nivolumab-significantly-improves-12-month-nccrcc-survival-in-sunniforecast 2024-09-14T22:01:40+00:00 weekly 0.7 https://trial.medpath.com/news/innovative-heart-valve-technology-could-improve-patient-lives-news-medical 2024-09-14T21:50:12+00:00 weekly 0.7 https://trial.medpath.com/news/enfortumab-vedotin-effective-in-patients-with-urothelial-cancer-outside-of-clinical-trials 2024-09-14T21:26:59+00:00 weekly 0.7 https://trial.medpath.com/news/united-states-remote-climate-control-market-by-application-2024-2031-third-eye-news 2024-09-14T21:17:36+00:00 weekly 0.7 https://trial.medpath.com/news/andrea-banty-np-dnp-navigating-new-developments-in-ibd-therapeutics-hcplive 2024-09-14T21:15:08+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-test-firm-oncologica-looking-to-raise-cash-this-is-money 2024-09-14T20:56:52+00:00 weekly 0.7 https://trial.medpath.com/news/retifanlimab-plus-carboplatin-meets-pfs-end-point-in-metastatic-scac-cancer-network 2024-09-14T20:31:39+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-radium-223-to-enzalutamide-significantly-improves-rpfs-and-os-in-mcrpc 2024-09-14T20:18:04+00:00 weekly 0.7 https://trial.medpath.com/news/safety-activity-seen-with-frontline-zanidatamab-plus-chemo-bevacizumab-in-her2-mcrc 2024-09-14T20:04:59+00:00 weekly 0.7 https://trial.medpath.com/news/diabetes-drug-may-lower-death-rate-in-obese-people-study-the-hindu 2024-09-14T20:00:17+00:00 weekly 0.7 https://trial.medpath.com/news/zipalertinib-shows-promise-in-heavily-pretreated-egfr-exon-20-mutated-nsclc 2024-09-14T19:23:56+00:00 weekly 0.7 https://trial.medpath.com/news/adjuvant-pembrolizumab-chemotherapy-fails-to-improve-dfs-high-risk-endometrial-cancer 2024-09-14T19:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/first-of-its-kind-colorectal-cancer-data-from-prospective-galaxy-study-released-at-esmo 2024-09-14T18:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/encorafenib-binimetinib-exhibits-anti-tumor-activity-in-untreated-braf-mutant-advanced-nsclc 2024-09-14T18:24:44+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-dato-dxd-plus-durvalumab-shows-variable-pcr-rates-in-stage-ii-iii-breast-cancer 2024-09-14T18:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-invited-discussant-optimizing-post-io-therapy-in-clear-cell-rcc-and 2024-09-14T17:41:31+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-s-karxt-faces-fda-approval-hurdles-analyst-issues-sell-rating-amid 2024-09-14T17:26:42+00:00 weekly 0.7 https://trial.medpath.com/news/first-line-t-dxd-combinations-show-early-antitumor-activity-in-her2-gastric-gej-cancers 2024-09-14T17:09:31+00:00 weekly 0.7 https://trial.medpath.com/news/study-ev-103-dose-escalation-cohort-a-5y-follow-up-of-first-line-enfortumab-vedotin 2024-09-14T16:53:10+00:00 weekly 0.7 https://trial.medpath.com/news/tigit-drug-from-iteos-shrinks-lung-tumors-in-trial-biopharma-dive 2024-09-14T16:51:27+00:00 weekly 0.7 https://trial.medpath.com/news/rybrevant-shows-colorectal-cancer-promise-in-latest-bispecifics-win-biocentury 2024-09-14T16:46:43+00:00 weekly 0.7 https://trial.medpath.com/news/effect-of-aortic-valve-replacement-on-myocardial-perfusion-and-exercise-capacity-in-patients 2024-09-14T16:39:21+00:00 weekly 0.7 https://trial.medpath.com/news/data-support-pembrolizumab-regimen-as-new-standard-for-advanced-cervical-cancer 2024-09-14T16:39:07+00:00 weekly 0.7 https://trial.medpath.com/news/colorado-researcher-says-people-with-ptsd-are-losing-out-on-an-effective-treatment 2024-09-14T16:02:27+00:00 weekly 0.7 https://trial.medpath.com/news/bl-b01d1-shows-favorable-phase-2-efficacy-safety-for-urothelial-carcinoma-urology-times 2024-09-14T15:01:14+00:00 weekly 0.7 https://trial.medpath.com/news/checkpoint-inhibitor-staves-off-disease-progression-in-anal-cancer-trial-stat-news 2024-09-14T14:48:00+00:00 weekly 0.7 https://trial.medpath.com/news/keytruda-r-pembrolizumab-plus-lenvima-r-lenvatinib-in-combination-with 2024-09-14T14:39:28+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-keytruda-r-pembrolizumab-plus-chemoradiotherapy-crt-reduced-risk-of 2024-09-14T14:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/niktimvo-for-the-treatment-of-cgvhd-us-clinical-trials-arena 2024-09-14T14:16:20+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-presents-positive-data-from-phase-2-study-of-ponsegromab-in-patients-with-cancer-cachexia 2024-09-14T13:40:20+00:00 weekly 0.7 https://trial.medpath.com/news/company-statement-on-fda-advisory-committee-meeting-biospace 2024-09-14T13:14:52+00:00 weekly 0.7 https://trial.medpath.com/news/icmr-to-advance-1st-in-human-trials-for-zika-flu-blood-cancer-therapies-health-news 2024-09-14T12:38:54+00:00 weekly 0.7 https://trial.medpath.com/news/gut-microbiome-emerges-as-key-player-in-cancer-immunotherapy-response-new-research-shows 2024-09-14T12:35:11+00:00 weekly 0.7 https://trial.medpath.com/news/maui-derm-np-pa-fall-2024-conference-to-spotlight-latest-advances-in-dermatology-treatment 2024-09-14T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dr-jonathan-riess-on-the-potential-of-io102-io103-the-cancer-vaccine-landscape 2024-09-14T11:37:51+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-new-leadership-and-groundbreaking-developments-in-oncology-research-and-patient-care 2024-09-14T11:17:39+00:00 weekly 0.7 https://trial.medpath.com/news/experts-highlight-new-dermatological-treatments-importance-of-clinical-trial-diversity 2024-09-14T11:06:45+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-alzheimer-s-drug-to-slow-disease-progression-nbc26 2024-09-14T10:59:56+00:00 weekly 0.7 https://trial.medpath.com/news/what-happened-in-optometry-this-week-september-9 2024-09-14T10:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/ocudyne-completes-successful-pilot-study-of-optic-system-ophthalmology-times 2024-09-14T10:18:11+00:00 weekly 0.7 https://trial.medpath.com/news/correction-to-eli-lilly-gets-fda-approval-for-eczema-treatment-article-morningstar 2024-09-14T10:15:19+00:00 weekly 0.7 https://trial.medpath.com/news/less-toxic-cancer-therapies-for-healthier-lives-featured-research-seattle-children-s 2024-09-14T09:45:52+00:00 weekly 0.7